{
  "file_name": "CUAD_v1/full_contract_pdf\\Part_I\\Development\\AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement.pdf",
  "annotations": [
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Document Name_0",
      "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
      "answer_text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
      "page_number": 0,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ],
          "confidence": 0.9972044229507446
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 0,
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ]
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "page": 0,
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ]
        },
        {
          "text": "XENCOR, INC.",
          "page": 0,
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ]
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "page": 0,
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Aimmune",
      "page_number": 0,
      "words": [
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ],
          "confidence": 0.9924952983856201
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 0,
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ]
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "page": 0,
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ]
        },
        {
          "text": "XENCOR, INC.",
          "page": 0,
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ]
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "page": 0,
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Parties_2",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Xencor and Aimmune are sometimes referred to herein individually as a \"Party\" and collectively as the \"Parties\".",
      "page_number": 2,
      "words": [
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Xencor, Inc.",
      "page_number": 0,
      "words": [
        {
          "text": "XENCOR, INC.",
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ],
          "confidence": 0.9703187942504883
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 0,
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ]
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "page": 0,
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ]
        },
        {
          "text": "XENCOR, INC.",
          "page": 0,
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ]
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "page": 0,
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Xencor",
      "page_number": 0,
      "words": [
        {
          "text": "XENCOR, INC.",
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ],
          "confidence": 0.9703187942504883
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 0,
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ]
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "page": 0,
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ]
        },
        {
          "text": "XENCOR, INC.",
          "page": 0,
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ]
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "page": 0,
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Aimmune Therapeutics, Inc.",
      "page_number": 0,
      "words": [
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ],
          "confidence": 0.9924952983856201
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 0,
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ]
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "page": 0,
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ]
        },
        {
          "text": "XENCOR, INC.",
          "page": 0,
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ]
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "page": 0,
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Agreement Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
      "answer_text": "FEBRUARY 4, 2020",
      "page_number": 0,
      "words": [
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ],
          "confidence": 0.9708194732666016
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 0,
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ]
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "page": 0,
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ]
        },
        {
          "text": "XENCOR, INC.",
          "page": 0,
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ]
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "page": 0,
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Effective Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effectiveÂ ",
      "answer_text": "February 4, 2020",
      "page_number": 0,
      "words": [
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ],
          "confidence": 0.9708194732666016
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 0,
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ]
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "page": 0,
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ]
        },
        {
          "text": "XENCOR, INC.",
          "page": 0,
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ]
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "page": 0,
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Expiration Date_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this ARTICLE 13, shall remain in effect on a Product-by-Product and country-by-country basis until the expiration of the Royalty Term applicable to such Product and country (the \"Term\").",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.3",
          "bbox": [
            2835.0,
            283.0,
            3056.0,
            322.0
          ],
          "confidence": 0.9996052384376526
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            279.0,
            389.0,
            3034.0,
            435.0
          ],
          "confidence": 0.9883718490600586
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            274.0,
            446.0,
            1718.0,
            490.0
          ],
          "confidence": 0.9940534234046936
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2751.0,
            524.0,
            3056.0,
            576.0
          ],
          "confidence": 0.9972357749938965
        },
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ],
          "confidence": 0.9972044229507446
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ],
          "confidence": 0.9708194732666016
        },
        {
          "text": "BY AND BETWEEN",
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ],
          "confidence": 0.9989999532699585
        },
        {
          "text": "XENCOR, INC.",
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ],
          "confidence": 0.9703187942504883
        },
        {
          "text": "AND",
          "bbox": [
            1622.0,
            967.0,
            1716.0,
            1007.0
          ],
          "confidence": 0.9991505742073059
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ],
          "confidence": 0.9924952983856201
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9902650713920593
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 0,
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ]
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "page": 0,
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ]
        },
        {
          "text": "XENCOR, INC.",
          "page": 0,
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ]
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "page": 0,
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Expiration Date_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this ARTICLE 13, shall remain in effect on a Product-by-Product and country-by-country basis until the expiration of the Royalty Term applicable to such Product and country (the \"Term\").",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Governing Law_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement shall be governed by and construed in accordance with the internal laws of the State of California applicable to agreements made and to be performed entirely within such state, without regard to the conflicts of law principles of such state; provided that any matters relating to the construction or effect of any Patent will be governed by the patent laws of the relevant jurisdiction in which such Patent is granted.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Governing Law_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement shall be governed by and construed in accordance with the internal laws of the State of California applicable to agreements made and to be performed entirely within such state, without regard to the conflicts of law principles of such state; provided that any matters relating to the construction or effect of any Patent will be governed by the patent laws of the relevant jurisdiction in which such Patent is granted.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Non-Compete_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "Aimmune covenants that it will not research or develop (including Develop) the Antibody itself, including not developing any modification, variant, fragment, progeny or derivatives of such Antibody, in each case, in a way that would produce a molecule that is neither the Antibody nor a molecule that falls within the definition of a Product.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Non-Compete_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "Aimmune covenants that it will not research or develop (including Develop) the Antibody itself, including not developing any modification, variant, fragment, progeny or derivatives of such Antibody, in each case, in a way that would produce a molecule that is neither the Antibody nor a molecule that falls within the definition of a Product.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Non-Compete_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "Aimmune hereby covenants and agrees that it shall not (and shall cause the other Aimmune Agreement Entities not to), either directly or indirectly, 14\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n\n\n\n\nDevelop, Manufacture, or Commercialize the Product for use outside the Licensed Field.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.3",
          "bbox": [
            2835.0,
            283.0,
            3056.0,
            322.0
          ],
          "confidence": 0.9996052384376526
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            279.0,
            389.0,
            3034.0,
            435.0
          ],
          "confidence": 0.9883718490600586
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            274.0,
            446.0,
            1718.0,
            490.0
          ],
          "confidence": 0.9940534234046936
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2751.0,
            524.0,
            3056.0,
            576.0
          ],
          "confidence": 0.9972357749938965
        },
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ],
          "confidence": 0.9972044229507446
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ],
          "confidence": 0.9708194732666016
        },
        {
          "text": "BY AND BETWEEN",
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ],
          "confidence": 0.9989999532699585
        },
        {
          "text": "XENCOR, INC.",
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ],
          "confidence": 0.9703187942504883
        },
        {
          "text": "AND",
          "bbox": [
            1622.0,
            967.0,
            1716.0,
            1007.0
          ],
          "confidence": 0.9991505742073059
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ],
          "confidence": 0.9924952983856201
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9902650713920593
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 0,
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ]
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "page": 0,
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ]
        },
        {
          "text": "XENCOR, INC.",
          "page": 0,
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ]
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "page": 0,
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Non-Compete_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": "Aimmune hereby covenants and agrees that it shall not (and shall cause the other Aimmune Agreement Entities not to), either directly or indirectly, 14\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n\n\n\n\nDevelop, Manufacture, or Commercialize the Product for use outside the Licensed Field.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Non-Compete_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": ". Furthermore, Xencor hereby covenants and agrees that it shall not (and shall cause its Affiliates not to), either directly or through granting a license or other right to, or otherwise facilitating, a Third Party to (a) Develop, Manufacture or Commercialize the Antibody or the Product during the Term, (b) commence any [***] of any [***] that is not the Antibody or a Product and that [***] for use in the Licensed Field, prior to the [***] ([***]t h) anniversary of the Effective Date, or (c) Develop, Manufacture or Commercialize any [***] that is not the Antibody or a Product and that [***] for use in the Aimmune Field during the Term.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.3",
          "bbox": [
            2835.0,
            283.0,
            3056.0,
            322.0
          ],
          "confidence": 0.9996052384376526
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            279.0,
            389.0,
            3034.0,
            435.0
          ],
          "confidence": 0.9883718490600586
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            274.0,
            446.0,
            1718.0,
            490.0
          ],
          "confidence": 0.9940534234046936
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2751.0,
            524.0,
            3056.0,
            576.0
          ],
          "confidence": 0.9972357749938965
        },
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ],
          "confidence": 0.9972044229507446
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ],
          "confidence": 0.9708194732666016
        },
        {
          "text": "BY AND BETWEEN",
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ],
          "confidence": 0.9989999532699585
        },
        {
          "text": "XENCOR, INC.",
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ],
          "confidence": 0.9703187942504883
        },
        {
          "text": "AND",
          "bbox": [
            1622.0,
            967.0,
            1716.0,
            1007.0
          ],
          "confidence": 0.9991505742073059
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ],
          "confidence": 0.9924952983856201
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9902650713920593
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 0,
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ]
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "page": 0,
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ]
        },
        {
          "text": "XENCOR, INC.",
          "page": 0,
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ]
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "page": 0,
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Non-Compete_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?Â ",
      "answer_text": ". Furthermore, Xencor hereby covenants and agrees that it shall not (and shall cause its Affiliates not to), either directly or through granting a license or other right to, or otherwise facilitating, a Third Party to (a) Develop, Manufacture or Commercialize the Antibody or the Product during the Term, (b) commence any [***] of any [***] that is not the Antibody or a Product and that [***] for use in the Licensed Field, prior to the [***] ([***]t h) anniversary of the Effective Date, or (c) Develop, Manufacture or Commercialize any [***] that is not the Antibody or a Product and that [***] for use in the Aimmune Field during the Term.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Subject to the terms and conditions of this Agreement, Xencor hereby grants to Aimmune during the Term an exclusive, worldwide, payment-bearing license under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents, and a non-exclusive, payment bearing license under and with respect to Xencor Know-How, in each case, with the right to sublicense solely in accordance with Section 2.3.2, solely to Develop, Manufacture and Commercialize the Product in and for the Licensed Field; provided that notwithstanding the foregoing, Xencor shall retain the right under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents to the extent necessary to perform its obligations under this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Exclusivity_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Subject to the terms and conditions of this Agreement, Xencor hereby grants to Aimmune during the Term an exclusive, worldwide, payment-bearing license under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents, and a non-exclusive, payment bearing license under and with respect to Xencor Know-How, in each case, with the right to sublicense solely in accordance with Section 2.3.2, solely to Develop, Manufacture and Commercialize the Product in and for the Licensed Field; provided that notwithstanding the foregoing, Xencor shall retain the right under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents to the extent necessary to perform its obligations under this Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Exclusivity_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Aimmune hereby grants to Xencor an exclusive license under and with respect to Aimmune Patents, and a non-exclusive license under and with respect to Aimmune Know-How, in each case, where such license is an irrevocable, perpetual, royalty-bearing license, with the right to sublicense, to Develop, Manufacture and Commercialize the Product(s), as the Product(s) exist as of the effective date of such termination, or optimized",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.3",
          "bbox": [
            2835.0,
            283.0,
            3056.0,
            322.0
          ],
          "confidence": 0.9996052384376526
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            279.0,
            389.0,
            3034.0,
            435.0
          ],
          "confidence": 0.9883718490600586
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            274.0,
            446.0,
            1718.0,
            490.0
          ],
          "confidence": 0.9940534234046936
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2751.0,
            524.0,
            3056.0,
            576.0
          ],
          "confidence": 0.9972357749938965
        },
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ],
          "confidence": 0.9972044229507446
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ],
          "confidence": 0.9708194732666016
        },
        {
          "text": "BY AND BETWEEN",
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ],
          "confidence": 0.9989999532699585
        },
        {
          "text": "XENCOR, INC.",
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ],
          "confidence": 0.9703187942504883
        },
        {
          "text": "AND",
          "bbox": [
            1622.0,
            967.0,
            1716.0,
            1007.0
          ],
          "confidence": 0.9991505742073059
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ],
          "confidence": 0.9924952983856201
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9902650713920593
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 0,
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ]
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "page": 0,
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ]
        },
        {
          "text": "XENCOR, INC.",
          "page": 0,
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ]
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "page": 0,
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Aimmune hereby grants to Xencor an exclusive license under and with respect to Aimmune Patents, and a non-exclusive license under and with respect to Aimmune Know-How, in each case, where such license is an irrevocable, perpetual, royalty-bearing license, with the right to sublicense, to Develop, Manufacture and Commercialize the Product(s), as the Product(s) exist as of the effective date of such termination, or optimized",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Termination For Convenience_16",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate thisÂ  contract without cause (solely by giving a notice and allowing a waitingÂ  period to expire)?",
      "answer_text": "Aimmune may terminate this Agreement in its entirety at any time for its convenience upon sixty (60) days' prior written notice to Xencor.",
      "page_number": 16,
      "words": [
        {
          "text": "Develop, Manufacture, or Commercialize the Product for use outside the Licensed Field. Furthermore, Xencor hereby covenants and agrees that it shall",
          "bbox": [
            279.0,
            296.0,
            3003.0,
            333.0
          ],
          "confidence": 0.9883972406387329
        },
        {
          "text": "not (and shall cause its Affiliates-not to), either directly or through granting a license or other right to, or otherwise facilitating, a Third Party to (a)",
          "bbox": [
            276.0,
            349.0,
            2913.0,
            391.0
          ],
          "confidence": 0.9982377290725708
        },
        {
          "text": "Develop, Manufacture or Commercialize the Antibody or the Product during the Term, (b) commence any [***] of any [***] that is not the Antibody or a",
          "bbox": [
            277.0,
            404.0,
            3043.0,
            446.0
          ],
          "confidence": 0.9918746948242188
        },
        {
          "text": "Product and that [***] for use in the Licensed Field, prior to the [***] ([***]th) anniversary of the Effective Date, or (c) Develop, Manufacture or",
          "bbox": [
            274.0,
            455.0,
            2904.0,
            501.0
          ],
          "confidence": 0.9963389039039612
        },
        {
          "text": "Commercialize any [***] that is not the Antibody or a Product and that [***] for use in the Aimmune Field during the Term. It is the desire and intent of",
          "bbox": [
            274.0,
            504.0,
            3021.0,
            557.0
          ],
          "confidence": 0.9980829954147339
        },
        {
          "text": "the Parties that the restrictive covenants contained in this Section 2.4 be enforced to the fullest extent permissible under Applicable Laws and public",
          "bbox": [
            277.0,
            566.0,
            2956.0,
            607.0
          ],
          "confidence": 0.9936452507972717
        },
        {
          "text": "policies applied in each jurisdiction in which enforcement is sought. Xencor and Aimmune believe that the restrictive covenants in this Section 2.4 are.",
          "bbox": [
            277.0,
            621.0,
            2985.0,
            663.0
          ],
          "confidence": 0.9934981465339661
        },
        {
          "text": "valid and enforceable. However, if any restrictive covenant should for any reason become or be declared by a competent court or competition authority to",
          "bbox": [
            277.0,
            676.0,
            3052.0,
            716.0
          ],
          "confidence": 0.9953952431678772
        },
        {
          "text": "be invalid or unenforceable in any jurisdiction, such restrictive covenant shall be deemed to have been amended to the extent necessary in order that.",
          "bbox": [
            274.0,
            727.0,
            2971.0,
            773.0
          ],
          "confidence": 0.9889947772026062
        },
        {
          "text": "such provision be valid and enforceable, such amendment shall apply only with respect to the operation of such provision of this Section 2.4 in the",
          "bbox": [
            279.0,
            788.0,
            2934.0,
            824.0
          ],
          "confidence": 0.9934779405593872
        },
        {
          "text": "particular jurisdiction in which such declaration is made. Further, both Parties agree that [***] of this Agreement..",
          "bbox": [
            275.0,
            837.0,
            2318.0,
            883.0
          ],
          "confidence": 0.9879477024078369
        },
        {
          "text": "2.5 Progress Updates. Aimmune shall keep Xencor informed as to its progress and activities relating to the Development, Manufacture and",
          "bbox": [
            388.0,
            945.0,
            2907.0,
            990.0
          ],
          "confidence": 0.9956866502761841
        },
        {
          "text": "Commercialization of the Product on [***] basis (i.e., every [***] ([***]) months), including by providing updates on the status of studies necessary for",
          "bbox": [
            277.0,
            1003.0,
            3036.0,
            1047.0
          ],
          "confidence": 0.9978579878807068
        },
        {
          "text": "obtaining Regulatory Approval with respect to the Product, regulatory matters and meetings with Regulatory Authorities with respect to the Product, and",
          "bbox": [
            279.0,
            1058.0,
            3058.0,
            1100.0
          ],
          "confidence": 0.9950051307678223
        },
        {
          "text": "Commercialization activities commencing no later than [***] ([***]) year prior to the date on which Aimmune estimates the First Commercial Sale of",
          "bbox": [
            277.0,
            1111.0,
            2947.0,
            1155.0
          ],
          "confidence": 0.9988638758659363
        },
        {
          "text": "Product will occur. Additionally, to the extent applicable, such updates shall include summaries of Aimmune's Development plans for the Product for the",
          "bbox": [
            276.0,
            1164.0,
            3025.0,
            1206.0
          ],
          "confidence": 0.996577799320221
        },
        {
          "text": "ensuing [***] ([***]) year time period. Any information disclosed under this Section 2.5 shall be treated as Confidential Information as defined in Section",
          "bbox": [
            277.0,
            1221.0,
            3050.0,
            1265.0
          ],
          "confidence": 0.9923104643821716
        },
        {
          "text": "12.1.",
          "bbox": [
            277.0,
            1274.0,
            362.0,
            1316.0
          ],
          "confidence": 0.9398804903030396
        },
        {
          "text": "2.6 Upstream Agreement. During the Term, neither Xencor nor any of its Affiliates shall (a) encumber any GPEx Technology, as defined in the",
          "bbox": [
            388.0,
            1383.0,
            2949.0,
            1425.0
          ],
          "confidence": 0.9911710023880005
        },
        {
          "text": "Upstream Agreement, to the extent included within the Xencor Technology, or commit any act or permit the occurrence of any omission that would cause",
          "bbox": [
            277.0,
            1436.0,
            3041.0,
            1482.0
          ],
          "confidence": 0.9940832853317261
        },
        {
          "text": "the breach or termination of the Upstream Agreement, or otherwise knowingly take actions or permit omissions that would adversely affect the rights.",
          "bbox": [
            277.0,
            1493.0,
            2967.0,
            1535.0
          ],
          "confidence": 0.9939767122268677
        },
        {
          "text": "granted to Aimmune hereunder with respect to the Xencor Patents and Xencor Know-How, or (b) without Aimmune's prior written consent, amend or",
          "bbox": [
            275.0,
            1544.0,
            2974.0,
            1592.0
          ],
          "confidence": 0.9899783134460449
        },
        {
          "text": "otherwise modify or permit to be amended or modified, the Upstream Agreement in any respect that would adversely affect Aimmune's rights with respect",
          "bbox": [
            275.0,
            1601.0,
            3058.0,
            1645.0
          ],
          "confidence": 0.9958216547966003
        },
        {
          "text": "to, the Antibody or Products. Xencor shall promptly notify Aimmune upon Xencor's becoming aware of any alleged, threatened, or actual breach of the",
          "bbox": [
            276.0,
            1657.0,
            3020.0,
            1699.0
          ],
          "confidence": 0.9953141808509827
        },
        {
          "text": "Upstream Agreement by either Party and shall not take any action that would reasonably give rise to the right of the counterparty to terminate the",
          "bbox": [
            279.0,
            1712.0,
            2914.0,
            1754.0
          ],
          "confidence": 0.9960122108459473
        },
        {
          "text": "Upstream Agreement.",
          "bbox": [
            281.0,
            1769.0,
            672.0,
            1805.0
          ],
          "confidence": 0.999098539352417
        },
        {
          "text": "2.7 Technology Transfer. Xencor shall use Commercially Reasonable Efforts to transfer, and Aimmune shall use Commercially Reasonable Efforts",
          "bbox": [
            388.0,
            1875.0,
            3011.0,
            1917.0
          ],
          "confidence": 0.997759997844696
        },
        {
          "text": "to receive, the Xencor Know-How, Regulatory Materials, and Regulatory Data, in each case, as identified on Schedule 2.7 to",
          "bbox": [
            276.0,
            1928.0,
            2514.0,
            1970.0
          ],
          "confidence": 0.9951580166816711
        },
        {
          "text": "15",
          "bbox": [
            1642.0,
            1983.0,
            1691.0,
            2023.0
          ],
          "confidence": 0.9926819801330566
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.99093097448349
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Termination For Convenience_8",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate thisÂ  contract without cause (solely by giving a notice and allowing a waitingÂ  period to expire)?",
      "answer_text": "Without limitation of its rights under this ARTICLE 13, Xencor may also terminate this Agreement in its entirety as applicable, pursuant to the provisions of Section 9.7.",
      "page_number": 8,
      "words": [
        {
          "text": "1.41 \"Invented' means the acts of (an) inventor(s), as determined in accordance with Applicable Law relating to inventorship set forth in the patent",
          "bbox": [
            388.0,
            294.0,
            3056.0,
            334.0
          ],
          "confidence": 0.9971361756324768
        },
        {
          "text": "laws of the United States (Title 35, United States Code), in first conceiving an Invention..",
          "bbox": [
            277.0,
            347.0,
            1863.0,
            389.0
          ],
          "confidence": 0.9970631003379822
        },
        {
          "text": "1.42 \"Invention\"' means any discovery or invention, whether or not patentable, conceived or otherwise made by either Party, or by both Parties, in",
          "bbox": [
            388.0,
            455.0,
            3031.0,
            499.0
          ],
          "confidence": 0.9953272342681885
        },
        {
          "text": "exercising its rights or performing its obligations under this Agreement..",
          "bbox": [
            279.0,
            513.0,
            1564.0,
            554.0
          ],
          "confidence": 0.9801538586616516
        },
        {
          "text": "1.43 \"Joint Invention\"' means an Invention that is Invented jointly by an employee of, or Person under an obligation of assignment to, each of",
          "bbox": [
            388.0,
            621.0,
            2969.0,
            663.0
          ],
          "confidence": 0.9836422801017761
        },
        {
          "text": "Xencor and Aimmune or their respective Affiliates.",
          "bbox": [
            276.0,
            676.0,
            1193.0,
            713.0
          ],
          "confidence": 0.9988651871681213
        },
        {
          "text": "1.44 \"Know-How\"' means all technical, scientific, regulatory and other information, results, knowledge, techniques and data, in whatever form and",
          "bbox": [
            390.0,
            784.0,
            3020.0,
            826.0
          ],
          "confidence": 0.9922977685928345
        },
        {
          "text": "whether or not confidential, patented or patentable, including Inventions, invention disclosures, discoveries, plans, processes, practices, methods,",
          "bbox": [
            275.0,
            837.0,
            2929.0,
            883.0
          ],
          "confidence": 0.9975293278694153
        },
        {
          "text": "knowledge, trade secrets, know-how, instructions, skill, experience, ideas, concepts, data (including biological, chemical, pharmacological, toxicological",
          "bbox": [
            279.0,
            897.0,
            3005.0,
            934.0
          ],
          "confidence": 0.9935280084609985
        },
        {
          "text": "pharmaceutical, physical and analytical, safety, quality control, and preclinical and clinical data), formulae, formulations, compositions, specifications,",
          "bbox": [
            277.0,
            947.0,
            2974.0,
            992.0
          ],
          "confidence": 0.9983097910881042
        },
        {
          "text": "marketing, pricing, distribution, cost, sales and manufacturing data or descriptions. Know-How does not include any Patent claiming any of the",
          "bbox": [
            276.0,
            1003.0,
            2866.0,
            1047.0
          ],
          "confidence": 0.9908810257911682
        },
        {
          "text": "foregoing.",
          "bbox": [
            273.0,
            1056.0,
            463.0,
            1104.0
          ],
          "confidence": 0.9990291595458984
        },
        {
          "text": "1.45 \"Licensed Field\"' means the diagnosis, treatment or prevention of human diseases and conditions..",
          "bbox": [
            390.0,
            1166.0,
            2266.0,
            1208.0
          ],
          "confidence": 0.989619255065918
        },
        {
          "text": "1.46 \"Major Territory\" means the [***].",
          "bbox": [
            390.0,
            1274.0,
            1136.0,
            1318.0
          ],
          "confidence": 0.9783608913421631
        },
        {
          "text": "1.47 \"Manufacture\" or \"Manufacturing' or \"Manufactured\" means, with respect to the Antibody and Product, the receipt, handling and storage",
          "bbox": [
            388.0,
            1380.0,
            3034.0,
            1427.0
          ],
          "confidence": 0.9748772978782654
        },
        {
          "text": "of Active Ingredients, drug substance or drug product, medical devices and other materials, the manufacturing, processing, Packaging and Labeling,",
          "bbox": [
            275.0,
            1434.0,
            2960.0,
            1486.0
          ],
          "confidence": 0.9983310699462891
        },
        {
          "text": "holding (including storage), quality assurance and quality control testing (including release) of the Antibody and Product (other than quality assurance",
          "bbox": [
            275.0,
            1491.0,
            3021.0,
            1539.0
          ],
          "confidence": 0.9970060586929321
        },
        {
          "text": "and quality control related to development of the manufacturing process, which activities shall be considered Development Activities) and shipping of",
          "bbox": [
            277.0,
            1546.0,
            3007.0,
            1592.0
          ],
          "confidence": 0.9905925989151001
        },
        {
          "text": "the Antibody and Product..",
          "bbox": [
            277.0,
            1604.0,
            761.0,
            1641.0
          ],
          "confidence": 0.9906022548675537
        },
        {
          "text": "1.48 \"Marketing Authorization Application' or \"MAA' means an application to the appropriate Regulatory Authority for approval to sell the",
          "bbox": [
            390.0,
            1710.0,
            2971.0,
            1754.0
          ],
          "confidence": 0.988331139087677
        },
        {
          "text": "Product (but excluding Pricing Approval) in any particular country or regulatory jurisdiction, including a Biologics License Application as described in 21",
          "bbox": [
            277.0,
            1765.0,
            3045.0,
            1809.0
          ],
          "confidence": 0.9965344071388245
        },
        {
          "text": "C.F.R. s601.2, as amended.",
          "bbox": [
            279.0,
            1820.0,
            752.0,
            1860.0
          ],
          "confidence": 0.9802960753440857
        },
        {
          "text": "1.49 \"Medical Science Liaison' means an individual who is employed by or on behalf of Aimmune or its Affiliates and who provides educational",
          "bbox": [
            388.0,
            1928.0,
            3025.0,
            1970.0
          ],
          "confidence": 0.99540776014328
        },
        {
          "text": "services and other educational efforts directed towards the medical and/or scientific community..",
          "bbox": [
            277.0,
            1981.0,
            2005.0,
            2027.0
          ],
          "confidence": 0.9960222244262695
        },
        {
          "text": "7",
          "bbox": [
            1653.0,
            2039.0,
            1682.0,
            2076.0
          ],
          "confidence": 0.986823558807373
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9909570813179016
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Rofr/Rofo/Rofn_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "Collaboration Patent to expire or intends to otherwise abandon any such Xencor Product Specific Patent, Aimmune Patent Covering an Antibody or Product or Joint Collaboration Patent, or (ii) decides not to prepare or file patent applications Covering Aimmune Inventions or Joint Inventions, Aimmune shall notify Xencor of such intention or decision at least [***] ([***]) days (or as soon as possible if less than [***] ([***]) days) prior to any filing or payment due date, or any other date that requires action, in connection with such Xencor Product Specific Patent, Aimmune Patent Covering an Antibody or Product or Joint Collaboration Patent, and Xencor shall thereupon have the right, but not the obligation, to assume responsibility for the preparation, filing, prosecution or maintenance thereof [***], in the name of Xencor or Aimmune, as applicable.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Rofr/Rofo/Rofn_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "Collaboration Patent to expire or intends to otherwise abandon any such Xencor Product Specific Patent, Aimmune Patent Covering an Antibody or Product or Joint Collaboration Patent, or (ii) decides not to prepare or file patent applications Covering Aimmune Inventions or Joint Inventions, Aimmune shall notify Xencor of such intention or decision at least [***] ([***]) days (or as soon as possible if less than [***] ([***]) days) prior to any filing or payment due date, or any other date that requires action, in connection with such Xencor Product Specific Patent, Aimmune Patent Covering an Antibody or Product or Joint Collaboration Patent, and Xencor shall thereupon have the right, but not the obligation, to assume responsibility for the preparation, filing, prosecution or maintenance thereof [***], in the name of Xencor or Aimmune, as applicable.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Rofr/Rofo/Rofn_1",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If, during the Term, Aimmune (i) intends to allow any Xencor Product Specific Patent, Aimmune Patent Covering an Antibody or Product or Joint",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other Party, except that a Party may make such an assignment or transfer without the other Party's written consent to (a) any of its Affiliates, in whole or in part, or (b) any Third Party in connection with (i) the acquisition of such Party by or merger or consolidation of such Party with another entity or (ii) a merger, consolidation, sale of stock, sale of all or substantially all of such Party's assets or other similar transaction in which such Third Party either becomes the owner of all or substantially all of the business and assets of (y) such Party or (z) that portion of such Party's business or business unit relating to this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Anti-Assignment_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other Party, except that a Party may make such an assignment or transfer without the other Party's written consent to (a) any of its Affiliates, in whole or in part, or (b) any Third Party in connection with (i) the acquisition of such Party by or merger or consolidation of such Party with another entity or (ii) a merger, consolidation, sale of stock, sale of all or substantially all of such Party's assets or other similar transaction in which such Third Party either becomes the owner of all or substantially all of the business and assets of (y) such Party or (z) that portion of such Party's business or business unit relating to this Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Anti-Assignment_2",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Any assignment or transfer, or attempted assignment or transfer, by either Party in violation of the terms of this Section 15.6 shall be null and void and of no legal effect.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Revenue/Profit Sharing_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "Within [***] ([***]) days after the Effective Date of this Agreement, Aimmune shall issue to Xencor shares of Aimmune Common Stock (the \"Shares\") in accordance with that certain Stock Issuance Agreement, dated the date hereof, by and among Xencor and Aimmune (the \"Stock Issuance Agreement\"), and pay to Xencor by wire transfer of immediately available funds, into an account designated in writing by Xencor, an amount equal to five million Dollars ($5,000,000) (together with the issuance of the Shares, the \"Upfront Payment\").",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Revenue/Profit Sharing_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "Within [***] ([***]) days after the Effective Date of this Agreement, Aimmune shall issue to Xencor shares of Aimmune Common Stock (the \"Shares\") in accordance with that certain Stock Issuance Agreement, dated the date hereof, by and among Xencor and Aimmune (the \"Stock Issuance Agreement\"), and pay to Xencor by wire transfer of immediately available funds, into an account designated in writing by Xencor, an amount equal to five million Dollars ($5,000,000) (together with the issuance of the Shares, the \"Upfront Payment\").",
      "page_number": 3,
      "words": [
        {
          "text": "1.3 \"Aimmune Agreement Entities\"' means Aimmune's Affiliates and Sublicensees (excluding distributors)",
          "bbox": [
            390.0,
            292.0,
            2338.0,
            336.0
          ],
          "confidence": 0.9935991764068604
        },
        {
          "text": "1.4 \"Aimmune Common Stock'' means Aimmune's common stock, par value $0.0001 per share",
          "bbox": [
            391.0,
            402.0,
            2103.0,
            442.0
          ],
          "confidence": 0.981459379196167
        },
        {
          "text": "1.5 \"Aimmune Field' means the field of [***].",
          "bbox": [
            388.0,
            508.0,
            1233.0,
            554.0
          ],
          "confidence": 0.9712823033332825
        },
        {
          "text": "1.6 \"Aimmune Invention' means an Invention that is Invented, solely or jointly with a Third Party, by or on behalf of Aimmune or its Affiliates.",
          "bbox": [
            388.0,
            618.0,
            2974.0,
            663.0
          ],
          "confidence": 0.9865084886550903
        },
        {
          "text": "1.7 \"Aimmune Know-How\" means any and all Know-How, whether or not patented or patentable, that is Controlled by Aimmune or its Affiliates as",
          "bbox": [
            390.0,
            729.0,
            3047.0,
            769.0
          ],
          "confidence": 0.9896785020828247
        },
        {
          "text": "of the Effective Date or at any time during the Term that is necessary or reasonably useful in connection with the Development, Manufacture,",
          "bbox": [
            275.0,
            782.0,
            2831.0,
            828.0
          ],
          "confidence": 0.9936000108718872
        },
        {
          "text": "Commercialization or other use of the Antibody or Product.",
          "bbox": [
            277.0,
            839.0,
            1343.0,
            879.0
          ],
          "confidence": 0.9995146989822388
        },
        {
          "text": "1.8 \"Aimmune Patent'' means any Patent that (i) (a) is Controlled by Aimmune (or its Affiliates) as of the Effective Date or comes under the",
          "bbox": [
            388.0,
            945.0,
            2913.0,
            989.0
          ],
          "confidence": 0.9862771034240723
        },
        {
          "text": "Control of Aimmune (or its Affiliates) during the Term (other than as a result of the licenses granted by Xencor to Aimmune under this Agreement) and",
          "bbox": [
            277.0,
            1003.0,
            3003.0,
            1045.0
          ],
          "confidence": 0.9990835785865784
        },
        {
          "text": "(b) that would be infringed by the Development, Manufacture, Commercialization or use of the Antibody or Product or that claims or Covers Aimmune",
          "bbox": [
            283.0,
            1060.0,
            2989.0,
            1096.0
          ],
          "confidence": 0.9943405389785767
        },
        {
          "text": "Know-How, or (ii) is an Aimmune Collaboration Patent.",
          "bbox": [
            281.0,
            1117.0,
            1263.0,
            1148.0
          ],
          "confidence": 0.9957587122917175
        },
        {
          "text": "1.9 \"Aimmune Technology' means Aimmune Know-How and Aimmune Patents.",
          "bbox": [
            388.0,
            1217.0,
            1851.0,
            1261.0
          ],
          "confidence": 0.9875858426094055
        },
        {
          "text": "1.10 \"Antibody' means Xencor's humanized antibody known as XmAb7195 having the sequence listed in Schedule 1.10.",
          "bbox": [
            390.0,
            1328.0,
            2574.0,
            1371.0
          ],
          "confidence": 0.9897436499595642
        },
        {
          "text": "1.11 \"Anti-Corruption Laws\" means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, as well as",
          "bbox": [
            388.0,
            1434.0,
            2889.0,
            1478.0
          ],
          "confidence": 0.9914922714233398
        },
        {
          "text": "Applicable Law related to the prevention of fraud, racketeering, money laundering or terrorism.",
          "bbox": [
            281.0,
            1495.0,
            1988.0,
            1537.0
          ],
          "confidence": 0.9964950680732727
        },
        {
          "text": "1.12 \"Applicable Law\"' means any applicable United States federal, state or local or foreign or multinational law, statute, standard, ordinance, code,",
          "bbox": [
            386.0,
            1599.0,
            3040.0,
            1645.0
          ],
          "confidence": 0.9866900444030762
        },
        {
          "text": "rule, regulation, resolution or promulgation, or any order, writ, judgment, injunction, decree, stipulation, ruling, determination or award entered by or with",
          "bbox": [
            276.0,
            1657.0,
            3029.0,
            1699.0
          ],
          "confidence": 0.9940216541290283
        },
        {
          "text": "any Governmental Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force",
          "bbox": [
            277.0,
            1712.0,
            3052.0,
            1754.0
          ],
          "confidence": 0.9971250891685486
        },
        {
          "text": "or effect of law. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall be deemed to include all then-",
          "bbox": [
            274.0,
            1763.0,
            2976.0,
            1809.0
          ],
          "confidence": 0.9982315897941589
        },
        {
          "text": "current amendments thereto or any replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, order, writ, judgment",
          "bbox": [
            276.0,
            1822.0,
            2982.0,
            1864.0
          ],
          "confidence": 0.9947020411491394
        },
        {
          "text": "injunction, decree, stipulation, ruling, or determination thereto.",
          "bbox": [
            277.0,
            1875.0,
            1405.0,
            1915.0
          ],
          "confidence": 0.9998493790626526
        },
        {
          "text": "2",
          "bbox": [
            1651.0,
            1930.0,
            1682.0,
            1966.0
          ],
          "confidence": 0.9919590950012207
        },
        {
          "text": "SourCe: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9840355515480042
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Revenue/Profit Sharing_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "On a country-by-country and Product-by-Product basis, if at any time during the Royalty Term with respect to such country and such Product there is one or more Generic Product(s) with respect to such Product being sold for [***]) consecutive Calendar Quarters, then [***] for such country and such Product, the royalty rate for such Product shall be reduced, after giving effect to any reduction applicable to such Product in such country pursuant to [***], on a Calendar Quarter basis as follows:\n\n(i) if the cumulative Net Sales of such Product in such country during such Calendar Quarter are equal to or less than [***] percent ([***]%), but are greater than [***] percent ([***]%), of the Baseline Quarter Net Sales, then the royalty rate will be reduced for such Calendar Quarter by [***] percent ([***]%); and\n\n(ii) if the cumulative Net Sales of such Product in such country during such Calendar Quarter are less than [***] percent ([***]%) of the Baseline Quarter Net Sales of the Baseline Quarter Net Sales, then the royalty rate for such Calendar Quarter will be reduced by [***] percent ([***]%).\n\nprovided, that, for clarity, on a country-by-country and Product-by-Product basis, there will be no royalty rate reduction with respect to a given country and Product pursuant to this Section 7.3.2(c) with respect to the initial [***] ([***]) consecutive Calendar Quarter periods during which Generic Product entry with respect to such Product and such country is being established.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Revenue/Profit Sharing_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "On a country-by-country and Product-by-Product basis, if at any time during the Royalty Term with respect to such country and such Product there is one or more Generic Product(s) with respect to such Product being sold for [***]) consecutive Calendar Quarters, then [***] for such country and such Product, the royalty rate for such Product shall be reduced, after giving effect to any reduction applicable to such Product in such country pursuant to [***], on a Calendar Quarter basis as follows:\n\n(i) if the cumulative Net Sales of such Product in such country during such Calendar Quarter are equal to or less than [***] percent ([***]%), but are greater than [***] percent ([***]%), of the Baseline Quarter Net Sales, then the royalty rate will be reduced for such Calendar Quarter by [***] percent ([***]%); and\n\n(ii) if the cumulative Net Sales of such Product in such country during such Calendar Quarter are less than [***] percent ([***]%) of the Baseline Quarter Net Sales of the Baseline Quarter Net Sales, then the royalty rate for such Calendar Quarter will be reduced by [***] percent ([***]%).\n\nprovided, that, for clarity, on a country-by-country and Product-by-Product basis, there will be no royalty rate reduction with respect to a given country and Product pursuant to this Section 7.3.2(c) with respect to the initial [***] ([***]) consecutive Calendar Quarter periods during which Generic Product entry with respect to such Product and such country is being established.",
      "page_number": 3,
      "words": [
        {
          "text": "1.3 \"Aimmune Agreement Entities\"' means Aimmune's Affiliates and Sublicensees (excluding distributors)",
          "bbox": [
            390.0,
            292.0,
            2338.0,
            336.0
          ],
          "confidence": 0.9935991764068604
        },
        {
          "text": "1.4 \"Aimmune Common Stock'' means Aimmune's common stock, par value $0.0001 per share",
          "bbox": [
            391.0,
            402.0,
            2103.0,
            442.0
          ],
          "confidence": 0.981459379196167
        },
        {
          "text": "1.5 \"Aimmune Field' means the field of [***].",
          "bbox": [
            388.0,
            508.0,
            1233.0,
            554.0
          ],
          "confidence": 0.9712823033332825
        },
        {
          "text": "1.6 \"Aimmune Invention' means an Invention that is Invented, solely or jointly with a Third Party, by or on behalf of Aimmune or its Affiliates.",
          "bbox": [
            388.0,
            618.0,
            2974.0,
            663.0
          ],
          "confidence": 0.9865084886550903
        },
        {
          "text": "1.7 \"Aimmune Know-How\" means any and all Know-How, whether or not patented or patentable, that is Controlled by Aimmune or its Affiliates as",
          "bbox": [
            390.0,
            729.0,
            3047.0,
            769.0
          ],
          "confidence": 0.9896785020828247
        },
        {
          "text": "of the Effective Date or at any time during the Term that is necessary or reasonably useful in connection with the Development, Manufacture,",
          "bbox": [
            275.0,
            782.0,
            2831.0,
            828.0
          ],
          "confidence": 0.9936000108718872
        },
        {
          "text": "Commercialization or other use of the Antibody or Product.",
          "bbox": [
            277.0,
            839.0,
            1343.0,
            879.0
          ],
          "confidence": 0.9995146989822388
        },
        {
          "text": "1.8 \"Aimmune Patent'' means any Patent that (i) (a) is Controlled by Aimmune (or its Affiliates) as of the Effective Date or comes under the",
          "bbox": [
            388.0,
            945.0,
            2913.0,
            989.0
          ],
          "confidence": 0.9862771034240723
        },
        {
          "text": "Control of Aimmune (or its Affiliates) during the Term (other than as a result of the licenses granted by Xencor to Aimmune under this Agreement) and",
          "bbox": [
            277.0,
            1003.0,
            3003.0,
            1045.0
          ],
          "confidence": 0.9990835785865784
        },
        {
          "text": "(b) that would be infringed by the Development, Manufacture, Commercialization or use of the Antibody or Product or that claims or Covers Aimmune",
          "bbox": [
            283.0,
            1060.0,
            2989.0,
            1096.0
          ],
          "confidence": 0.9943405389785767
        },
        {
          "text": "Know-How, or (ii) is an Aimmune Collaboration Patent.",
          "bbox": [
            281.0,
            1117.0,
            1263.0,
            1148.0
          ],
          "confidence": 0.9957587122917175
        },
        {
          "text": "1.9 \"Aimmune Technology' means Aimmune Know-How and Aimmune Patents.",
          "bbox": [
            388.0,
            1217.0,
            1851.0,
            1261.0
          ],
          "confidence": 0.9875858426094055
        },
        {
          "text": "1.10 \"Antibody' means Xencor's humanized antibody known as XmAb7195 having the sequence listed in Schedule 1.10.",
          "bbox": [
            390.0,
            1328.0,
            2574.0,
            1371.0
          ],
          "confidence": 0.9897436499595642
        },
        {
          "text": "1.11 \"Anti-Corruption Laws\" means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, as well as",
          "bbox": [
            388.0,
            1434.0,
            2889.0,
            1478.0
          ],
          "confidence": 0.9914922714233398
        },
        {
          "text": "Applicable Law related to the prevention of fraud, racketeering, money laundering or terrorism.",
          "bbox": [
            281.0,
            1495.0,
            1988.0,
            1537.0
          ],
          "confidence": 0.9964950680732727
        },
        {
          "text": "1.12 \"Applicable Law\"' means any applicable United States federal, state or local or foreign or multinational law, statute, standard, ordinance, code,",
          "bbox": [
            386.0,
            1599.0,
            3040.0,
            1645.0
          ],
          "confidence": 0.9866900444030762
        },
        {
          "text": "rule, regulation, resolution or promulgation, or any order, writ, judgment, injunction, decree, stipulation, ruling, determination or award entered by or with",
          "bbox": [
            276.0,
            1657.0,
            3029.0,
            1699.0
          ],
          "confidence": 0.9940216541290283
        },
        {
          "text": "any Governmental Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force",
          "bbox": [
            277.0,
            1712.0,
            3052.0,
            1754.0
          ],
          "confidence": 0.9971250891685486
        },
        {
          "text": "or effect of law. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall be deemed to include all then-",
          "bbox": [
            274.0,
            1763.0,
            2976.0,
            1809.0
          ],
          "confidence": 0.9982315897941589
        },
        {
          "text": "current amendments thereto or any replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, order, writ, judgment",
          "bbox": [
            276.0,
            1822.0,
            2982.0,
            1864.0
          ],
          "confidence": 0.9947020411491394
        },
        {
          "text": "injunction, decree, stipulation, ruling, or determination thereto.",
          "bbox": [
            277.0,
            1875.0,
            1405.0,
            1915.0
          ],
          "confidence": 0.9998493790626526
        },
        {
          "text": "2",
          "bbox": [
            1651.0,
            1930.0,
            1682.0,
            1966.0
          ],
          "confidence": 0.9919590950012207
        },
        {
          "text": "SourCe: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9840355515480042
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Revenue/Profit Sharing_13_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "Under the terms of the agreement, Aimmune will make an upfront payment to Xencor of $5 million in cash and $5 million in equity, equivalent to 156,238 newly issued shares of Aimmune common stock at $32.0025/share.",
      "page_number": 13,
      "words": [
        {
          "text": "1.74 \"Valid Claim'' means, with respect to a particular country, (i) a claim of [***] that (a) has not been specifically held permanently revoked.",
          "bbox": [
            388.0,
            291.0,
            2958.0,
            334.0
          ],
          "confidence": 0.9884636402130127
        },
        {
          "text": "unenforceable or invalid by a decision of a court or other Governmental Authority of competent jurisdiction, which decision is unappealed or.",
          "bbox": [
            277.0,
            349.0,
            2826.0,
            389.0
          ],
          "confidence": 0.991759181022644
        },
        {
          "text": "unappealable within the time allowed for appeal, and (b) has not been cancelled, withdrawn, abandoned, disclaimed or admitted to be invalid or",
          "bbox": [
            274.0,
            400.0,
            2857.0,
            446.0
          ],
          "confidence": 0.9950385093688965
        },
        {
          "text": "unenforceable through reissue, disclaimer or otherwise, or (ii) a bona fide claim of a pending patent application [***] that has not been (a) cancelled,",
          "bbox": [
            276.0,
            457.0,
            2954.0,
            499.0
          ],
          "confidence": 0.9950246214866638
        },
        {
          "text": "withdrawn or abandoned without being re-filed in another application in the applicable jurisdiction, or (b) finally rejected by an administrative agency",
          "bbox": [
            275.0,
            508.0,
            2971.0,
            557.0
          ],
          "confidence": 0.9968777894973755
        },
        {
          "text": "action from which no appeal can be taken or that has not been appealed within the time allowed for appeal.",
          "bbox": [
            275.0,
            565.0,
            2204.0,
            610.0
          ],
          "confidence": 0.9940816164016724
        },
        {
          "text": "1.75 \"Variant' means [***]",
          "bbox": [
            390.0,
            674.0,
            908.0,
            718.0
          ],
          "confidence": 0.9644771814346313
        },
        {
          "text": "1.76 \"Xencor [***]\" means a [***]",
          "bbox": [
            390.0,
            782.0,
            1042.0,
            826.0
          ],
          "confidence": 0.9783087968826294
        },
        {
          "text": "1.77 \"Xencor Invention\"' means an Invention that is Invented solely or jointly with a Third Party, by or on behalf of Xencor or its Affiliates.",
          "bbox": [
            388.0,
            890.0,
            2905.0,
            936.0
          ],
          "confidence": 0.9917380809783936
        },
        {
          "text": "1.78 \"Xencor Know-How\" means any and all Know-How, whether or not patented or patentable, (i) to the extent Controlled by Xencor or its.",
          "bbox": [
            388.0,
            1000.0,
            2918.0,
            1043.0
          ],
          "confidence": 0.9866036772727966
        },
        {
          "text": "Affiliates as of the Effective Date, or, if transferred to Aimmune thereafter during the Term of this Agreement, and that is necessary in connection with the",
          "bbox": [
            279.0,
            1056.0,
            3050.0,
            1098.0
          ],
          "confidence": 0.9939122200012207
        },
        {
          "text": "Development, Manufacture, Commercialization or other use of the Antibody or Product or (ii) constituting a Xencor Invention. Notwithstanding the",
          "bbox": [
            279.0,
            1115.0,
            2944.0,
            1151.0
          ],
          "confidence": 0.9992824196815491
        },
        {
          "text": "[***] l) 1o [***] (e) [***] (p) [***] () [***] (q) [***] (e) npnneu! gou seop moh-mouy nonuex sesen [[e u! Bunonaao]",
          "bbox": [
            274.0,
            1162.0,
            2467.0,
            1213.0
          ],
          "confidence": 0.7786532640457153
        },
        {
          "text": "Schedule 1.79, (ii) with respect to such Patents set forth on Schedule 1.79, all provisional applications, substitutions, continuations, continuations-in-part,",
          "bbox": [
            275.0,
            1327.0,
            3054.0,
            1372.0
          ],
          "confidence": 0.9932160973548889
        },
        {
          "text": "divisionals, renewals, patents-of-addition, reissues, reexaminations and extensions, (iii) all international and domestic counterparts of any of the",
          "bbox": [
            277.0,
            1381.0,
            2875.0,
            1425.0
          ],
          "confidence": 0.99580979347229
        },
        {
          "text": "foregoing, and (iv) any other Patents Controlled by Xencor that claim inventions necessary for the Development, Manufacture, Commercialization or",
          "bbox": [
            277.0,
            1434.0,
            2963.0,
            1482.0
          ],
          "confidence": 0.9996304512023926
        },
        {
          "text": "other use of the Antibody or Product as the Antibody and Product exist as of the Effective Date.",
          "bbox": [
            279.0,
            1495.0,
            2023.0,
            1531.0
          ],
          "confidence": 0.9977526664733887
        },
        {
          "text": "1.80 \"Xencor Patent\"' means Xencor General Patents and Xencor Product Specific Patents.",
          "bbox": [
            390.0,
            1601.0,
            2035.0,
            1641.0
          ],
          "confidence": 0.9877369999885559
        },
        {
          "text": "1.81 \"Xencor Product Specific Patent' means (i) the Patents identified on Schedule 1.81, including patents issuing from any patent application set",
          "bbox": [
            388.0,
            1707.0,
            3043.0,
            1754.0
          ],
          "confidence": 0.995611846446991
        },
        {
          "text": "forth on Schedule 1.81, (ii) with respect to all Patents set forth on Schedule 1.81, all provisional applications, substitutions, continuations, continuations-",
          "bbox": [
            275.0,
            1763.0,
            3031.0,
            1807.0
          ],
          "confidence": 0.9946943521499634
        },
        {
          "text": "in-part, divisionals, renewals, patents-of-addition, reissues, reexaminations and extensions, (ii) any [***], and (iv) all international and domestic",
          "bbox": [
            277.0,
            1820.0,
            2875.0,
            1862.0
          ],
          "confidence": 0.9968152046203613
        },
        {
          "text": "counterparts of any of the foregoing.",
          "bbox": [
            275.0,
            1873.0,
            943.0,
            1921.0
          ],
          "confidence": 0.9816625714302063
        },
        {
          "text": "1.82 \"Xencor Technology' means Xencor Know-How and Xencor Patents",
          "bbox": [
            390.0,
            1981.0,
            1745.0,
            2023.0
          ],
          "confidence": 0.9933408498764038
        },
        {
          "text": "12",
          "bbox": [
            1644.0,
            2036.0,
            1691.0,
            2078.0
          ],
          "confidence": 0.9978570938110352
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9839010238647461
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Revenue/Profit Sharing_14_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "Under the terms of the agreement, Aimmune will make an upfront payment to Xencor of $5 million in cash and $5 million in equity, equivalent to 156,238 newly issued shares of Aimmune common stock at $32.0025/share.",
      "page_number": 14,
      "words": [
        {
          "text": "1.83 Additional Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement:",
          "bbox": [
            388.0,
            292.0,
            2684.0,
            334.0
          ],
          "confidence": 0.9886758327484131
        },
        {
          "text": "Term",
          "bbox": [
            271.0,
            358.0,
            370.0,
            403.0
          ],
          "confidence": 0.9999105930328369
        },
        {
          "text": "Section",
          "bbox": [
            929.0,
            358.0,
            1070.0,
            402.0
          ],
          "confidence": 0.9996209740638733
        },
        {
          "text": "Term",
          "bbox": [
            1225.0,
            358.0,
            1324.0,
            403.0
          ],
          "confidence": 0.9999015927314758
        },
        {
          "text": "Section",
          "bbox": [
            1906.0,
            358.0,
            2047.0,
            402.0
          ],
          "confidence": 0.9995733499526978
        },
        {
          "text": "\"Agreement\"",
          "bbox": [
            272.0,
            406.0,
            538.0,
            455.0
          ],
          "confidence": 0.9911723732948303
        },
        {
          "text": "Preamble",
          "bbox": [
            932.0,
            409.0,
            1098.0,
            448.0
          ],
          "confidence": 0.9999244809150696
        },
        {
          "text": "\"Indemnified Party\"",
          "bbox": [
            1227.0,
            406.0,
            1610.0,
            453.0
          ],
          "confidence": 0.9824265837669373
        },
        {
          "text": "11.3.1",
          "bbox": [
            1907.0,
            406.0,
            2012.0,
            451.0
          ],
          "confidence": 0.9998965263366699
        },
        {
          "text": "\"Bankrupt Party\"",
          "bbox": [
            276.0,
            464.0,
            618.0,
            508.0
          ],
          "confidence": 0.9763033390045166
        },
        {
          "text": "14.7",
          "bbox": [
            932.0,
            462.0,
            1010.0,
            504.0
          ],
          "confidence": 0.9999525547027588
        },
        {
          "text": "\"Indemnifying Party\"",
          "bbox": [
            1225.0,
            459.0,
            1637.0,
            512.0
          ],
          "confidence": 0.9893218278884888
        },
        {
          "text": "11.3.1",
          "bbox": [
            1907.0,
            460.0,
            2010.0,
            501.0
          ],
          "confidence": 0.9998519420623779
        },
        {
          "text": "\"Breaching Party\"",
          "bbox": [
            279.0,
            519.0,
            633.0,
            563.0
          ],
          "confidence": 0.9828007817268372
        },
        {
          "text": "13.2",
          "bbox": [
            932.0,
            517.0,
            1010.0,
            559.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "\"Infringement Claim\".",
          "bbox": [
            1231.0,
            517.0,
            1648.0,
            561.0
          ],
          "confidence": 0.9683110117912292
        },
        {
          "text": "9.4.1",
          "bbox": [
            1907.0,
            517.0,
            1996.0,
            559.0
          ],
          "confidence": 0.999947190284729
        },
        {
          "text": "[***]",
          "bbox": [
            269.0,
            564.0,
            385.0,
            624.0
          ],
          "confidence": 0.9941298365592957
        },
        {
          "text": "1.73",
          "bbox": [
            930.0,
            572.0,
            1008.0,
            614.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "\"Joint Collaboration Patents'",
          "bbox": [
            1232.0,
            574.0,
            1784.0,
            610.0
          ],
          "confidence": 0.9765629768371582
        },
        {
          "text": "9.1.1",
          "bbox": [
            1907.0,
            572.0,
            1994.0,
            614.0
          ],
          "confidence": 0.9999370574951172
        },
        {
          "text": "\"Claim\"",
          "bbox": [
            274.0,
            625.0,
            439.0,
            669.0
          ],
          "confidence": 0.9820356369018555
        },
        {
          "text": "11.1",
          "bbox": [
            932.0,
            625.0,
            1004.0,
            669.0
          ],
          "confidence": 0.9997718334197998
        },
        {
          "text": "\"Aimmune\"",
          "bbox": [
            1227.0,
            623.0,
            1461.0,
            671.0
          ],
          "confidence": 0.9965857267379761
        },
        {
          "text": "Preamble",
          "bbox": [
            1909.0,
            625.0,
            2077.0,
            669.0
          ],
          "confidence": 0.9999080300331116
        },
        {
          "text": "\"CMC\"",
          "bbox": [
            272.0,
            676.0,
            426.0,
            720.0
          ],
          "confidence": 0.939008891582489
        },
        {
          "text": "1.66",
          "bbox": [
            927.0,
            677.0,
            1010.0,
            726.0
          ],
          "confidence": 0.9999576807022095
        },
        {
          "text": "\"Aimmune Collaboration",
          "bbox": [
            1227.0,
            680.0,
            1695.0,
            722.0
          ],
          "confidence": 0.9986696839332581
        },
        {
          "text": "9.1.1",
          "bbox": [
            1907.0,
            680.0,
            1994.0,
            722.0
          ],
          "confidence": 0.9999340176582336
        },
        {
          "text": "\"Commercialization Data\"",
          "bbox": [
            274.0,
            731.0,
            774.0,
            777.0
          ],
          "confidence": 0.9935369491577148
        },
        {
          "text": "5.5",
          "bbox": [
            930.0,
            733.0,
            990.0,
            778.0
          ],
          "confidence": 0.999841034412384
        },
        {
          "text": "Patents\"",
          "bbox": [
            1227.0,
            734.0,
            1398.0,
            777.0
          ],
          "confidence": 0.9897316694259644
        },
        {
          "text": "\"Confidential Information\"",
          "bbox": [
            277.0,
            789.0,
            781.0,
            831.0
          ],
          "confidence": 0.9800927639007568
        },
        {
          "text": "12.1.1",
          "bbox": [
            930.0,
            788.0,
            1039.0,
            833.0
          ],
          "confidence": 0.9306747317314148
        },
        {
          "text": "\"Xencor\"",
          "bbox": [
            1225.0,
            785.0,
            1416.0,
            834.0
          ],
          "confidence": 0.9505678415298462
        },
        {
          "text": "Preamble",
          "bbox": [
            1909.0,
            788.0,
            2077.0,
            831.0
          ],
          "confidence": 0.9999275207519531
        },
        {
          "text": "\"Controlling Party\"",
          "bbox": [
            274.0,
            842.0,
            651.0,
            890.0
          ],
          "confidence": 0.9441533088684082
        },
        {
          "text": "9.4.1(a)",
          "bbox": [
            928.0,
            840.0,
            1066.0,
            890.0
          ],
          "confidence": 0.9503344297409058
        },
        {
          "text": "\"Xencor Collaboration Patents\"",
          "bbox": [
            1231.0,
            846.0,
            1825.0,
            883.0
          ],
          "confidence": 0.9667111039161682
        },
        {
          "text": "9.1.1",
          "bbox": [
            1904.0,
            838.0,
            1995.0,
            891.0
          ],
          "confidence": 0.9251721501350403
        },
        {
          "text": "\"Court\"",
          "bbox": [
            273.0,
            895.0,
            437.0,
            943.0
          ],
          "confidence": 0.9075150489807129
        },
        {
          "text": "15.13.3",
          "bbox": [
            933.0,
            899.0,
            1058.0,
            939.0
          ],
          "confidence": 0.9999237656593323
        },
        {
          "text": "\"Losses\"",
          "bbox": [
            1229.0,
            897.0,
            1412.0,
            941.0
          ],
          "confidence": 0.9684075713157654
        },
        {
          "text": "11.1",
          "bbox": [
            1909.0,
            897.0,
            1981.0,
            941.0
          ],
          "confidence": 0.9997687339782715
        },
        {
          "text": "\"Dispute\"",
          "bbox": [
            276.0,
            952.0,
            469.0,
            998.0
          ],
          "confidence": 0.9877522587776184
        },
        {
          "text": "15.1",
          "bbox": [
            932.0,
            952.0,
            1008.0,
            994.0
          ],
          "confidence": 0.9999220371246338
        },
        {
          "text": "\"Packaging and Labeling\"",
          "bbox": [
            1229.0,
            952.0,
            1724.0,
            998.0
          ],
          "confidence": 0.988644540309906
        },
        {
          "text": "6.2",
          "bbox": [
            1907.0,
            952.0,
            1967.0,
            996.0
          ],
          "confidence": 0.999860942363739
        },
        {
          "text": "\"Effective Date\"",
          "bbox": [
            277.0,
            1009.0,
            576.0,
            1047.0
          ],
          "confidence": 0.9810457229614258
        },
        {
          "text": "Preamble",
          "bbox": [
            932.0,
            1009.0,
            1098.0,
            1047.0
          ],
          "confidence": 0.9999171495437622
        },
        {
          "text": "Term",
          "bbox": [
            1226.0,
            1052.0,
            1327.0,
            1097.0
          ],
          "confidence": 0.9998647570610046
        },
        {
          "text": "Section",
          "bbox": [
            1847.0,
            1052.0,
            1987.0,
            1097.0
          ],
          "confidence": 0.9993125200271606
        },
        {
          "text": "\"ICH\"",
          "bbox": [
            276.0,
            1062.0,
            401.0,
            1102.0
          ],
          "confidence": 0.9597446322441101
        },
        {
          "text": "1.34",
          "bbox": [
            930.0,
            1062.0,
            1010.0,
            1104.0
          ],
          "confidence": 0.9999852180480957
        },
        {
          "text": "\"Party\" or \"Parties\".",
          "bbox": [
            1231.0,
            1100.0,
            1630.0,
            1148.0
          ],
          "confidence": 0.9596141576766968
        },
        {
          "text": "Preamble",
          "bbox": [
            1847.0,
            1106.0,
            2016.0,
            1144.0
          ],
          "confidence": 0.9999344944953918
        },
        {
          "text": "\"Product Trade Dress\"",
          "bbox": [
            1234.0,
            1157.0,
            1666.0,
            1197.0
          ],
          "confidence": 0.9856714606285095
        },
        {
          "text": "5.4.1",
          "bbox": [
            1845.0,
            1157.0,
            1934.0,
            1199.0
          ],
          "confidence": 0.9999324679374695
        },
        {
          "text": "\"Product Trademark\"",
          "bbox": [
            1234.0,
            1213.0,
            1644.0,
            1252.0
          ],
          "confidence": 0.9866476655006409
        },
        {
          "text": "5.4.1",
          "bbox": [
            1847.0,
            1212.0,
            1934.0,
            1254.0
          ],
          "confidence": 0.9999446868896484
        },
        {
          "text": "\"Recovery\"",
          "bbox": [
            1230.0,
            1264.0,
            1454.0,
            1314.0
          ],
          "confidence": 0.9638071060180664
        },
        {
          "text": "9.4.2(c)(iv)",
          "bbox": [
            1845.0,
            1264.0,
            2043.0,
            1314.0
          ],
          "confidence": 0.9995567798614502
        },
        {
          "text": "\"Shares\"",
          "bbox": [
            1228.0,
            1315.0,
            1420.0,
            1367.0
          ],
          "confidence": 0.994845449924469
        },
        {
          "text": "7.1",
          "bbox": [
            1847.0,
            1319.0,
            1905.0,
            1365.0
          ],
          "confidence": 0.9997556805610657
        },
        {
          "text": "\"Stock Issuance Agreement\"",
          "bbox": [
            1229.0,
            1372.0,
            1782.0,
            1418.0
          ],
          "confidence": 0.9976216554641724
        },
        {
          "text": "7.1",
          "bbox": [
            1842.0,
            1371.0,
            1906.0,
            1421.0
          ],
          "confidence": 0.9998999238014221
        },
        {
          "text": "\"Sublicensee\"",
          "bbox": [
            1229.0,
            1425.0,
            1508.0,
            1473.0
          ],
          "confidence": 0.9844080805778503
        },
        {
          "text": "2.3.2",
          "bbox": [
            1845.0,
            1429.0,
            1934.0,
            1471.0
          ],
          "confidence": 0.9999364614486694
        },
        {
          "text": "\"Term\"",
          "bbox": [
            1231.0,
            1482.0,
            1383.0,
            1526.0
          ],
          "confidence": 0.959658682346344
        },
        {
          "text": "13.1",
          "bbox": [
            1847.0,
            1484.0,
            1923.0,
            1526.0
          ],
          "confidence": 0.9999340772628784
        },
        {
          "text": "\"Third Party Patent'.",
          "bbox": [
            1232.0,
            1537.0,
            1630.0,
            1584.0
          ],
          "confidence": 0.929969072341919
        },
        {
          "text": "7.3.2(b)",
          "bbox": [
            1845.0,
            1535.0,
            1985.0,
            1585.0
          ],
          "confidence": 0.9999509453773499
        },
        {
          "text": "\"Upfront Payment'",
          "bbox": [
            1234.0,
            1592.0,
            1593.0,
            1641.0
          ],
          "confidence": 0.9684739708900452
        },
        {
          "text": "7.1",
          "bbox": [
            1847.0,
            1592.0,
            1905.0,
            1637.0
          ],
          "confidence": 0.9998016357421875
        },
        {
          "text": "\"VAT\"",
          "bbox": [
            1228.0,
            1642.0,
            1363.0,
            1693.0
          ],
          "confidence": 0.9593393206596375
        },
        {
          "text": "8.3.3",
          "bbox": [
            1847.0,
            1648.0,
            1936.0,
            1690.0
          ],
          "confidence": 0.9999639391899109
        },
        {
          "text": "ARTICLE 2",
          "bbox": [
            1562.0,
            1741.0,
            1776.0,
            1778.0
          ],
          "confidence": 0.9988908767700195
        },
        {
          "text": "LICENSES",
          "bbox": [
            1562.0,
            1794.0,
            1771.0,
            1833.0
          ],
          "confidence": 0.9992284774780273
        },
        {
          "text": "2.1 Grant to Aimmune. Subject to the terms and conditions of this Agreement, Xencor hereby grants to Aimmune during the Term an exclusive",
          "bbox": [
            390.0,
            1900.0,
            2983.0,
            1946.0
          ],
          "confidence": 0.9990817904472351
        },
        {
          "text": "worldwide, payment-bearing license under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents, and a non-exclusive,",
          "bbox": [
            277.0,
            1959.0,
            3025.0,
            2003.0
          ],
          "confidence": 0.9978504180908203
        },
        {
          "text": "payment bearing license under and with respect to Xencor Know-How, in each case, with the right to sublicense solely in accordance with Section 2.3.2,",
          "bbox": [
            275.0,
            2010.0,
            3021.0,
            2059.0
          ],
          "confidence": 0.9941607713699341
        },
        {
          "text": "solely to Develop, Manufacture and Commercialize the Product in and for the Licensed Field; provided that notwithstanding the foregoing, Xencor shall",
          "bbox": [
            277.0,
            2069.0,
            3025.0,
            2111.0
          ],
          "confidence": 0.9937365055084229
        },
        {
          "text": "retain the right under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents to the extent necessary to perform its",
          "bbox": [
            276.0,
            2123.0,
            2934.0,
            2165.0
          ],
          "confidence": 0.9922593832015991
        },
        {
          "text": "obligations under this Agreement.",
          "bbox": [
            275.0,
            2174.0,
            897.0,
            2220.0
          ],
          "confidence": 0.999629020690918
        },
        {
          "text": "2.2 Additional Licensing Provisions.",
          "bbox": [
            390.0,
            2286.0,
            1057.0,
            2326.0
          ],
          "confidence": 0.9917773008346558
        },
        {
          "text": "2.2.1 Negative Covenant. Aimmune covenants that it will not use or practice any of Xencor's rights to and under the Xencor Patents.",
          "bbox": [
            527.0,
            2397.0,
            2922.0,
            2434.0
          ],
          "confidence": 0.9967155456542969
        },
        {
          "text": "Xencor Know-How or other intellectual property rights licensed (or sublicensed, as applicable) to it under this ARTICLE 2, except for the purposes",
          "bbox": [
            276.0,
            2450.0,
            2929.0,
            2492.0
          ],
          "confidence": 0.9954777359962463
        },
        {
          "text": "expressly permitted in the applicable license grant. Aimmune covenants that it will not research or develop (including Develop) the Antibody itself,",
          "bbox": [
            279.0,
            2503.0,
            2931.0,
            2545.0
          ],
          "confidence": 0.994195282459259
        },
        {
          "text": "including not developing any modification, variant, fragment, progeny or derivatives of such Antibody, in each case, in a way that would produce a",
          "bbox": [
            279.0,
            2558.0,
            2942.0,
            2600.0
          ],
          "confidence": 0.9901818037033081
        },
        {
          "text": "molecule that is neither the Antibody nor a molecule that falls within the definition of a Product.",
          "bbox": [
            277.0,
            2615.0,
            2005.0,
            2651.0
          ],
          "confidence": 0.997048020362854
        },
        {
          "text": "13",
          "bbox": [
            1644.0,
            2666.0,
            1689.0,
            2708.0
          ],
          "confidence": 0.9999074935913086
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9906539916992188
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "\"CMC\"",
          "page": 14,
          "bbox": [
            272.0,
            676.0,
            426.0,
            720.0
          ]
        },
        {
          "text": "\"ICH\"",
          "page": 14,
          "bbox": [
            276.0,
            1062.0,
            401.0,
            1102.0
          ]
        },
        {
          "text": "\"VAT\"",
          "page": 14,
          "bbox": [
            1228.0,
            1642.0,
            1363.0,
            1693.0
          ]
        },
        {
          "text": "ARTICLE 2",
          "page": 14,
          "bbox": [
            1562.0,
            1741.0,
            1776.0,
            1778.0
          ]
        },
        {
          "text": "LICENSES",
          "page": 14,
          "bbox": [
            1562.0,
            1794.0,
            1771.0,
            1833.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Revenue/Profit Sharing_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "If Aimmune obtains such a license to a Third Party Patent, Aimmune shall be entitled to credit [***] percent ([***]%) of the royalties paid to such Third Party during a Calendar Quarter against the royalty payment otherwise payable by Aimmune to Xencor pursuant to this Section 7.3 with respect to such Product and such country in such Calendar Quarter.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Revenue/Profit Sharing_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "If Aimmune obtains such a license to a Third Party Patent, Aimmune shall be entitled to credit [***] percent ([***]%) of the royalties paid to such Third Party during a Calendar Quarter against the royalty payment otherwise payable by Aimmune to Xencor pursuant to this Section 7.3 with respect to such Product and such country in such Calendar Quarter.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Revenue/Profit Sharing_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "On a country-by-country and Product-by-Product basis, if at any time during the Royalty Term with respect to such country and such Product, such Product is not Covered by any Valid Claim of a [***], the royalty rate applied to Net Sales of such Product shall be the royalty rate in Section 7.3.1 reduced by [***] percent ([***]%) for so long as during the Royalty Term such Product is not Covered by a Valid Claim of a [***] in such country.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.3",
          "bbox": [
            2835.0,
            283.0,
            3056.0,
            322.0
          ],
          "confidence": 0.9996052384376526
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            279.0,
            389.0,
            3034.0,
            435.0
          ],
          "confidence": 0.9883718490600586
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            274.0,
            446.0,
            1718.0,
            490.0
          ],
          "confidence": 0.9940534234046936
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2751.0,
            524.0,
            3056.0,
            576.0
          ],
          "confidence": 0.9972357749938965
        },
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ],
          "confidence": 0.9972044229507446
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ],
          "confidence": 0.9708194732666016
        },
        {
          "text": "BY AND BETWEEN",
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ],
          "confidence": 0.9989999532699585
        },
        {
          "text": "XENCOR, INC.",
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ],
          "confidence": 0.9703187942504883
        },
        {
          "text": "AND",
          "bbox": [
            1622.0,
            967.0,
            1716.0,
            1007.0
          ],
          "confidence": 0.9991505742073059
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ],
          "confidence": 0.9924952983856201
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9902650713920593
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 0,
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ]
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "page": 0,
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ]
        },
        {
          "text": "XENCOR, INC.",
          "page": 0,
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ]
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "page": 0,
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Revenue/Profit Sharing_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "On a country-by-country and Product-by-Product basis, if at any time during the Royalty Term with respect to such country and such Product, such Product is not Covered by any Valid Claim of a [***], the royalty rate applied to Net Sales of such Product shall be the royalty rate in Section 7.3.1 reduced by [***] percent ([***]%) for so long as during the Royalty Term such Product is not Covered by a Valid Claim of a [***] in such country.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Revenue/Profit Sharing_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "(d) Royalty Floor. Notwithstanding any provision set forth in this Agreement to the contrary, none of the permitted reductions to royalties provided in this Section 7.3.2 will reduce any royalty payment payable in a given Calendar Quarter with respect to Net Sales of any Product in any country during the Royalty Term by more than [***] percent ([***]%) of the royalties otherwise owed to Xencor pursuant to Section 7.3.1.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Revenue/Profit Sharing_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "(d) Royalty Floor. Notwithstanding any provision set forth in this Agreement to the contrary, none of the permitted reductions to royalties provided in this Section 7.3.2 will reduce any royalty payment payable in a given Calendar Quarter with respect to Net Sales of any Product in any country during the Royalty Term by more than [***] percent ([***]%) of the royalties otherwise owed to Xencor pursuant to Section 7.3.1.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Revenue/Profit Sharing_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "On a Product-by-Product and country-by-country basis during the Royalty Term applicable to such Product and such country, Aimmune shall pay to Xencor the following royalties on Net Sales of Products, subject to Section 7.3.2:\n\nAggregate Annual Net Sales Royalty Rate [***] [***]% [***] [***]% [***] [***]% [***] [***]% [***] [***]%",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Revenue/Profit Sharing_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "On a Product-by-Product and country-by-country basis during the Royalty Term applicable to such Product and such country, Aimmune shall pay to Xencor the following royalties on Net Sales of Products, subject to Section 7.3.2:\n\nAggregate Annual Net Sales Royalty Rate [***] [***]% [***] [***]% [***] [***]% [***] [***]% [***] [***]%",
      "page_number": 3,
      "words": [
        {
          "text": "1.3 \"Aimmune Agreement Entities\"' means Aimmune's Affiliates and Sublicensees (excluding distributors)",
          "bbox": [
            390.0,
            292.0,
            2338.0,
            336.0
          ],
          "confidence": 0.9935991764068604
        },
        {
          "text": "1.4 \"Aimmune Common Stock'' means Aimmune's common stock, par value $0.0001 per share",
          "bbox": [
            391.0,
            402.0,
            2103.0,
            442.0
          ],
          "confidence": 0.981459379196167
        },
        {
          "text": "1.5 \"Aimmune Field' means the field of [***].",
          "bbox": [
            388.0,
            508.0,
            1233.0,
            554.0
          ],
          "confidence": 0.9712823033332825
        },
        {
          "text": "1.6 \"Aimmune Invention' means an Invention that is Invented, solely or jointly with a Third Party, by or on behalf of Aimmune or its Affiliates.",
          "bbox": [
            388.0,
            618.0,
            2974.0,
            663.0
          ],
          "confidence": 0.9865084886550903
        },
        {
          "text": "1.7 \"Aimmune Know-How\" means any and all Know-How, whether or not patented or patentable, that is Controlled by Aimmune or its Affiliates as",
          "bbox": [
            390.0,
            729.0,
            3047.0,
            769.0
          ],
          "confidence": 0.9896785020828247
        },
        {
          "text": "of the Effective Date or at any time during the Term that is necessary or reasonably useful in connection with the Development, Manufacture,",
          "bbox": [
            275.0,
            782.0,
            2831.0,
            828.0
          ],
          "confidence": 0.9936000108718872
        },
        {
          "text": "Commercialization or other use of the Antibody or Product.",
          "bbox": [
            277.0,
            839.0,
            1343.0,
            879.0
          ],
          "confidence": 0.9995146989822388
        },
        {
          "text": "1.8 \"Aimmune Patent'' means any Patent that (i) (a) is Controlled by Aimmune (or its Affiliates) as of the Effective Date or comes under the",
          "bbox": [
            388.0,
            945.0,
            2913.0,
            989.0
          ],
          "confidence": 0.9862771034240723
        },
        {
          "text": "Control of Aimmune (or its Affiliates) during the Term (other than as a result of the licenses granted by Xencor to Aimmune under this Agreement) and",
          "bbox": [
            277.0,
            1003.0,
            3003.0,
            1045.0
          ],
          "confidence": 0.9990835785865784
        },
        {
          "text": "(b) that would be infringed by the Development, Manufacture, Commercialization or use of the Antibody or Product or that claims or Covers Aimmune",
          "bbox": [
            283.0,
            1060.0,
            2989.0,
            1096.0
          ],
          "confidence": 0.9943405389785767
        },
        {
          "text": "Know-How, or (ii) is an Aimmune Collaboration Patent.",
          "bbox": [
            281.0,
            1117.0,
            1263.0,
            1148.0
          ],
          "confidence": 0.9957587122917175
        },
        {
          "text": "1.9 \"Aimmune Technology' means Aimmune Know-How and Aimmune Patents.",
          "bbox": [
            388.0,
            1217.0,
            1851.0,
            1261.0
          ],
          "confidence": 0.9875858426094055
        },
        {
          "text": "1.10 \"Antibody' means Xencor's humanized antibody known as XmAb7195 having the sequence listed in Schedule 1.10.",
          "bbox": [
            390.0,
            1328.0,
            2574.0,
            1371.0
          ],
          "confidence": 0.9897436499595642
        },
        {
          "text": "1.11 \"Anti-Corruption Laws\" means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, as well as",
          "bbox": [
            388.0,
            1434.0,
            2889.0,
            1478.0
          ],
          "confidence": 0.9914922714233398
        },
        {
          "text": "Applicable Law related to the prevention of fraud, racketeering, money laundering or terrorism.",
          "bbox": [
            281.0,
            1495.0,
            1988.0,
            1537.0
          ],
          "confidence": 0.9964950680732727
        },
        {
          "text": "1.12 \"Applicable Law\"' means any applicable United States federal, state or local or foreign or multinational law, statute, standard, ordinance, code,",
          "bbox": [
            386.0,
            1599.0,
            3040.0,
            1645.0
          ],
          "confidence": 0.9866900444030762
        },
        {
          "text": "rule, regulation, resolution or promulgation, or any order, writ, judgment, injunction, decree, stipulation, ruling, determination or award entered by or with",
          "bbox": [
            276.0,
            1657.0,
            3029.0,
            1699.0
          ],
          "confidence": 0.9940216541290283
        },
        {
          "text": "any Governmental Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force",
          "bbox": [
            277.0,
            1712.0,
            3052.0,
            1754.0
          ],
          "confidence": 0.9971250891685486
        },
        {
          "text": "or effect of law. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall be deemed to include all then-",
          "bbox": [
            274.0,
            1763.0,
            2976.0,
            1809.0
          ],
          "confidence": 0.9982315897941589
        },
        {
          "text": "current amendments thereto or any replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, order, writ, judgment",
          "bbox": [
            276.0,
            1822.0,
            2982.0,
            1864.0
          ],
          "confidence": 0.9947020411491394
        },
        {
          "text": "injunction, decree, stipulation, ruling, or determination thereto.",
          "bbox": [
            277.0,
            1875.0,
            1405.0,
            1915.0
          ],
          "confidence": 0.9998493790626526
        },
        {
          "text": "2",
          "bbox": [
            1651.0,
            1930.0,
            1682.0,
            1966.0
          ],
          "confidence": 0.9919590950012207
        },
        {
          "text": "SourCe: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9840355515480042
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Volume Restriction_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Volume Restriction\" that should be reviewed by a lawyer. Details: Is there a fee increase or consent requirement, etc. if one partyâs use of the product/services exceeds certain threshold?",
      "answer_text": "Xencor will allocate adequate appropriately qualified representatives to enable Aimmune to practice and understand the Xencor Know-How, Regulatory Materials, and Regulatory Data, including in connection with the transition of Manufacturing responsibility to Aimmune, Xencor's obligations under this Section 2.7 shall not exceed an aggregate of [***] ([***]) full- time equivalent hours unless the Parties otherwise agree in writing [***].",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Volume Restriction_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Volume Restriction\" that should be reviewed by a lawyer. Details: Is there a fee increase or consent requirement, etc. if one partyâs use of the product/services exceeds certain threshold?",
      "answer_text": "Xencor will allocate adequate appropriately qualified representatives to enable Aimmune to practice and understand the Xencor Know-How, Regulatory Materials, and Regulatory Data, including in connection with the transition of Manufacturing responsibility to Aimmune, Xencor's obligations under this Section 2.7 shall not exceed an aggregate of [***] ([***]) full- time equivalent hours unless the Parties otherwise agree in writing [***].",
      "page_number": 3,
      "words": [
        {
          "text": "1.3 \"Aimmune Agreement Entities\"' means Aimmune's Affiliates and Sublicensees (excluding distributors)",
          "bbox": [
            390.0,
            292.0,
            2338.0,
            336.0
          ],
          "confidence": 0.9935991764068604
        },
        {
          "text": "1.4 \"Aimmune Common Stock'' means Aimmune's common stock, par value $0.0001 per share",
          "bbox": [
            391.0,
            402.0,
            2103.0,
            442.0
          ],
          "confidence": 0.981459379196167
        },
        {
          "text": "1.5 \"Aimmune Field' means the field of [***].",
          "bbox": [
            388.0,
            508.0,
            1233.0,
            554.0
          ],
          "confidence": 0.9712823033332825
        },
        {
          "text": "1.6 \"Aimmune Invention' means an Invention that is Invented, solely or jointly with a Third Party, by or on behalf of Aimmune or its Affiliates.",
          "bbox": [
            388.0,
            618.0,
            2974.0,
            663.0
          ],
          "confidence": 0.9865084886550903
        },
        {
          "text": "1.7 \"Aimmune Know-How\" means any and all Know-How, whether or not patented or patentable, that is Controlled by Aimmune or its Affiliates as",
          "bbox": [
            390.0,
            729.0,
            3047.0,
            769.0
          ],
          "confidence": 0.9896785020828247
        },
        {
          "text": "of the Effective Date or at any time during the Term that is necessary or reasonably useful in connection with the Development, Manufacture,",
          "bbox": [
            275.0,
            782.0,
            2831.0,
            828.0
          ],
          "confidence": 0.9936000108718872
        },
        {
          "text": "Commercialization or other use of the Antibody or Product.",
          "bbox": [
            277.0,
            839.0,
            1343.0,
            879.0
          ],
          "confidence": 0.9995146989822388
        },
        {
          "text": "1.8 \"Aimmune Patent'' means any Patent that (i) (a) is Controlled by Aimmune (or its Affiliates) as of the Effective Date or comes under the",
          "bbox": [
            388.0,
            945.0,
            2913.0,
            989.0
          ],
          "confidence": 0.9862771034240723
        },
        {
          "text": "Control of Aimmune (or its Affiliates) during the Term (other than as a result of the licenses granted by Xencor to Aimmune under this Agreement) and",
          "bbox": [
            277.0,
            1003.0,
            3003.0,
            1045.0
          ],
          "confidence": 0.9990835785865784
        },
        {
          "text": "(b) that would be infringed by the Development, Manufacture, Commercialization or use of the Antibody or Product or that claims or Covers Aimmune",
          "bbox": [
            283.0,
            1060.0,
            2989.0,
            1096.0
          ],
          "confidence": 0.9943405389785767
        },
        {
          "text": "Know-How, or (ii) is an Aimmune Collaboration Patent.",
          "bbox": [
            281.0,
            1117.0,
            1263.0,
            1148.0
          ],
          "confidence": 0.9957587122917175
        },
        {
          "text": "1.9 \"Aimmune Technology' means Aimmune Know-How and Aimmune Patents.",
          "bbox": [
            388.0,
            1217.0,
            1851.0,
            1261.0
          ],
          "confidence": 0.9875858426094055
        },
        {
          "text": "1.10 \"Antibody' means Xencor's humanized antibody known as XmAb7195 having the sequence listed in Schedule 1.10.",
          "bbox": [
            390.0,
            1328.0,
            2574.0,
            1371.0
          ],
          "confidence": 0.9897436499595642
        },
        {
          "text": "1.11 \"Anti-Corruption Laws\" means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, as well as",
          "bbox": [
            388.0,
            1434.0,
            2889.0,
            1478.0
          ],
          "confidence": 0.9914922714233398
        },
        {
          "text": "Applicable Law related to the prevention of fraud, racketeering, money laundering or terrorism.",
          "bbox": [
            281.0,
            1495.0,
            1988.0,
            1537.0
          ],
          "confidence": 0.9964950680732727
        },
        {
          "text": "1.12 \"Applicable Law\"' means any applicable United States federal, state or local or foreign or multinational law, statute, standard, ordinance, code,",
          "bbox": [
            386.0,
            1599.0,
            3040.0,
            1645.0
          ],
          "confidence": 0.9866900444030762
        },
        {
          "text": "rule, regulation, resolution or promulgation, or any order, writ, judgment, injunction, decree, stipulation, ruling, determination or award entered by or with",
          "bbox": [
            276.0,
            1657.0,
            3029.0,
            1699.0
          ],
          "confidence": 0.9940216541290283
        },
        {
          "text": "any Governmental Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force",
          "bbox": [
            277.0,
            1712.0,
            3052.0,
            1754.0
          ],
          "confidence": 0.9971250891685486
        },
        {
          "text": "or effect of law. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall be deemed to include all then-",
          "bbox": [
            274.0,
            1763.0,
            2976.0,
            1809.0
          ],
          "confidence": 0.9982315897941589
        },
        {
          "text": "current amendments thereto or any replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, order, writ, judgment",
          "bbox": [
            276.0,
            1822.0,
            2982.0,
            1864.0
          ],
          "confidence": 0.9947020411491394
        },
        {
          "text": "injunction, decree, stipulation, ruling, or determination thereto.",
          "bbox": [
            277.0,
            1875.0,
            1405.0,
            1915.0
          ],
          "confidence": 0.9998493790626526
        },
        {
          "text": "2",
          "bbox": [
            1651.0,
            1930.0,
            1682.0,
            1966.0
          ],
          "confidence": 0.9919590950012207
        },
        {
          "text": "SourCe: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9840355515480042
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Ip Ownership Assignment_1",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "The Aimmune Know- How shall be transferred pursuant to the procedure to transfer Xencor Know-How, Regulatory Materials, and Regulatory Data in Section 2.7 applied mutatis mutandis.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Upon the termination of this Agreement, Aimmune will promptly, in each case within [***] ([***]) days thereafter:\n\n(a) assign to Xencor, [***], all of Aimmune's right, title and interest in and to any agreements (or portions thereof) between Aimmune and Third Parties that relate to the Development, Commercialization or Manufacture of the Product, where such assignment is permitted without charge to Aimmune or its Affiliates and where Xencor shall assume all future payments due under any agreement assigned pursuant to this subsection;\n\n(b) assign to Xencor, [***], and subject to the execution of a standard trademark license between the Parties prior to such assignment, all of Aimmune's right, title and interest in and to any (i) Promotional Materials, (ii) copyrights and trademarks (including the Product Trademarks and Product Trade Dress), including any goodwill associated therewith, and any registrations and design patents for the foregoing, and (iii) any internet domain name registrations for such trademarks and slogans, all to the extent solely related to the Product; provided, however, in the event Xencor exercises such right to have assigned such Promotional Materials, Aimmune shall grant, and hereby does grant, a royalty-free right and license to any housemarks, trademarks, names and logos of Aimmune contained therein for a period of [***] ([***]) months in order to use such Promotional Materials solely in connection with the Commercialization of the Product;\n\n(c) assign to Xencor, [***], the management and continued performance of any Clinical Trials for the Product ongoing hereunder as of the effective date of such termination in respect of which Xencor shall assume full financial responsibility from and after the effective date of such termination;\n\n(d) transfer to Xencor all of Aimmune's right, title and interest in and to any and all regulatory filings, Regulatory Approvals and other Regulatory Materials for the Product;",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Ip Ownership Assignment_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Upon the termination of this Agreement, Aimmune will promptly, in each case within [***] ([***]) days thereafter:\n\n(a) assign to Xencor, [***], all of Aimmune's right, title and interest in and to any agreements (or portions thereof) between Aimmune and Third Parties that relate to the Development, Commercialization or Manufacture of the Product, where such assignment is permitted without charge to Aimmune or its Affiliates and where Xencor shall assume all future payments due under any agreement assigned pursuant to this subsection;\n\n(b) assign to Xencor, [***], and subject to the execution of a standard trademark license between the Parties prior to such assignment, all of Aimmune's right, title and interest in and to any (i) Promotional Materials, (ii) copyrights and trademarks (including the Product Trademarks and Product Trade Dress), including any goodwill associated therewith, and any registrations and design patents for the foregoing, and (iii) any internet domain name registrations for such trademarks and slogans, all to the extent solely related to the Product; provided, however, in the event Xencor exercises such right to have assigned such Promotional Materials, Aimmune shall grant, and hereby does grant, a royalty-free right and license to any housemarks, trademarks, names and logos of Aimmune contained therein for a period of [***] ([***]) months in order to use such Promotional Materials solely in connection with the Commercialization of the Product;\n\n(c) assign to Xencor, [***], the management and continued performance of any Clinical Trials for the Product ongoing hereunder as of the effective date of such termination in respect of which Xencor shall assume full financial responsibility from and after the effective date of such termination;\n\n(d) transfer to Xencor all of Aimmune's right, title and interest in and to any and all regulatory filings, Regulatory Approvals and other Regulatory Materials for the Product;",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "(e) transfer to Xencor all of Aimmune's right, title and interest in and to any and all Development-related data and Commercialization Data Controlled by Aimmune for the Product; and\n\n(f) provide a copy of (i) the material tangible embodiments of the foregoing and (ii) any other material books, records, files and documents Controlled by Aimmune solely to the extent related to the Product and which may be redacted to exclude Confidential Information of Aimmune;\n\nprovided, however, that to the extent that any agreement or other asset described in this Section 14.2 is not assignable by Aimmune (whether because such agreement or asset is explicitly non-assignable or because the Third Party consent required for such assignment is not obtained), then such agreement or other asset will not be assigned, and upon the request of Xencor, Aimmune will take such steps as may be reasonably necessary to allow Xencor to obtain and to enjoy the benefits of such agreement or other asset. For purposes of clarity, (1) [***] and (2) to the extent Xencor requests [***].",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Ip Ownership Assignment_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property createdÂ  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "(e) transfer to Xencor all of Aimmune's right, title and interest in and to any and all Development-related data and Commercialization Data Controlled by Aimmune for the Product; and\n\n(f) provide a copy of (i) the material tangible embodiments of the foregoing and (ii) any other material books, records, files and documents Controlled by Aimmune solely to the extent related to the Product and which may be redacted to exclude Confidential Information of Aimmune;\n\nprovided, however, that to the extent that any agreement or other asset described in this Section 14.2 is not assignable by Aimmune (whether because such agreement or asset is explicitly non-assignable or because the Third Party consent required for such assignment is not obtained), then such agreement or other asset will not be assigned, and upon the request of Xencor, Aimmune will take such steps as may be reasonably necessary to allow Xencor to obtain and to enjoy the benefits of such agreement or other asset. For purposes of clarity, (1) [***] and (2) to the extent Xencor requests [***].",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Joint Ip Ownership_3",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "All Joint Inventions shall be jointly owned by the Parties, and Patents Covering Joint Inventions shall be referred to as \"Joint Collaboration Patents\".",
      "page_number": 3,
      "words": [
        {
          "text": "1.3 \"Aimmune Agreement Entities\"' means Aimmune's Affiliates and Sublicensees (excluding distributors)",
          "bbox": [
            390.0,
            292.0,
            2338.0,
            336.0
          ],
          "confidence": 0.9935991764068604
        },
        {
          "text": "1.4 \"Aimmune Common Stock'' means Aimmune's common stock, par value $0.0001 per share",
          "bbox": [
            391.0,
            402.0,
            2103.0,
            442.0
          ],
          "confidence": 0.981459379196167
        },
        {
          "text": "1.5 \"Aimmune Field' means the field of [***].",
          "bbox": [
            388.0,
            508.0,
            1233.0,
            554.0
          ],
          "confidence": 0.9712823033332825
        },
        {
          "text": "1.6 \"Aimmune Invention' means an Invention that is Invented, solely or jointly with a Third Party, by or on behalf of Aimmune or its Affiliates.",
          "bbox": [
            388.0,
            618.0,
            2974.0,
            663.0
          ],
          "confidence": 0.9865084886550903
        },
        {
          "text": "1.7 \"Aimmune Know-How\" means any and all Know-How, whether or not patented or patentable, that is Controlled by Aimmune or its Affiliates as",
          "bbox": [
            390.0,
            729.0,
            3047.0,
            769.0
          ],
          "confidence": 0.9896785020828247
        },
        {
          "text": "of the Effective Date or at any time during the Term that is necessary or reasonably useful in connection with the Development, Manufacture,",
          "bbox": [
            275.0,
            782.0,
            2831.0,
            828.0
          ],
          "confidence": 0.9936000108718872
        },
        {
          "text": "Commercialization or other use of the Antibody or Product.",
          "bbox": [
            277.0,
            839.0,
            1343.0,
            879.0
          ],
          "confidence": 0.9995146989822388
        },
        {
          "text": "1.8 \"Aimmune Patent'' means any Patent that (i) (a) is Controlled by Aimmune (or its Affiliates) as of the Effective Date or comes under the",
          "bbox": [
            388.0,
            945.0,
            2913.0,
            989.0
          ],
          "confidence": 0.9862771034240723
        },
        {
          "text": "Control of Aimmune (or its Affiliates) during the Term (other than as a result of the licenses granted by Xencor to Aimmune under this Agreement) and",
          "bbox": [
            277.0,
            1003.0,
            3003.0,
            1045.0
          ],
          "confidence": 0.9990835785865784
        },
        {
          "text": "(b) that would be infringed by the Development, Manufacture, Commercialization or use of the Antibody or Product or that claims or Covers Aimmune",
          "bbox": [
            283.0,
            1060.0,
            2989.0,
            1096.0
          ],
          "confidence": 0.9943405389785767
        },
        {
          "text": "Know-How, or (ii) is an Aimmune Collaboration Patent.",
          "bbox": [
            281.0,
            1117.0,
            1263.0,
            1148.0
          ],
          "confidence": 0.9957587122917175
        },
        {
          "text": "1.9 \"Aimmune Technology' means Aimmune Know-How and Aimmune Patents.",
          "bbox": [
            388.0,
            1217.0,
            1851.0,
            1261.0
          ],
          "confidence": 0.9875858426094055
        },
        {
          "text": "1.10 \"Antibody' means Xencor's humanized antibody known as XmAb7195 having the sequence listed in Schedule 1.10.",
          "bbox": [
            390.0,
            1328.0,
            2574.0,
            1371.0
          ],
          "confidence": 0.9897436499595642
        },
        {
          "text": "1.11 \"Anti-Corruption Laws\" means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, as well as",
          "bbox": [
            388.0,
            1434.0,
            2889.0,
            1478.0
          ],
          "confidence": 0.9914922714233398
        },
        {
          "text": "Applicable Law related to the prevention of fraud, racketeering, money laundering or terrorism.",
          "bbox": [
            281.0,
            1495.0,
            1988.0,
            1537.0
          ],
          "confidence": 0.9964950680732727
        },
        {
          "text": "1.12 \"Applicable Law\"' means any applicable United States federal, state or local or foreign or multinational law, statute, standard, ordinance, code,",
          "bbox": [
            386.0,
            1599.0,
            3040.0,
            1645.0
          ],
          "confidence": 0.9866900444030762
        },
        {
          "text": "rule, regulation, resolution or promulgation, or any order, writ, judgment, injunction, decree, stipulation, ruling, determination or award entered by or with",
          "bbox": [
            276.0,
            1657.0,
            3029.0,
            1699.0
          ],
          "confidence": 0.9940216541290283
        },
        {
          "text": "any Governmental Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force",
          "bbox": [
            277.0,
            1712.0,
            3052.0,
            1754.0
          ],
          "confidence": 0.9971250891685486
        },
        {
          "text": "or effect of law. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall be deemed to include all then-",
          "bbox": [
            274.0,
            1763.0,
            2976.0,
            1809.0
          ],
          "confidence": 0.9982315897941589
        },
        {
          "text": "current amendments thereto or any replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, order, writ, judgment",
          "bbox": [
            276.0,
            1822.0,
            2982.0,
            1864.0
          ],
          "confidence": 0.9947020411491394
        },
        {
          "text": "injunction, decree, stipulation, ruling, or determination thereto.",
          "bbox": [
            277.0,
            1875.0,
            1405.0,
            1915.0
          ],
          "confidence": 0.9998493790626526
        },
        {
          "text": "2",
          "bbox": [
            1651.0,
            1930.0,
            1682.0,
            1966.0
          ],
          "confidence": 0.9919590950012207
        },
        {
          "text": "SourCe: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9840355515480042
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__License Grant_2",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Develop, Manufacture, or Commercialize the Product for use outside the Licensed Field.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Aimmune covenants that it will not research or develop (including Develop) the Antibody itself, including not developing any modification, variant, fragment, progeny or derivatives of such Antibody, in each case, in a way that would produce a molecule that is neither the Antibody nor a molecule that falls within the definition of a Product.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__License Grant_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Aimmune covenants that it will not research or develop (including Develop) the Antibody itself, including not developing any modification, variant, fragment, progeny or derivatives of such Antibody, in each case, in a way that would produce a molecule that is neither the Antibody nor a molecule that falls within the definition of a Product.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Aimmune hereby grants to Xencor an exclusive license under and with respect to Aimmune Patents, and a non-exclusive license under and with respect to Aimmune Know-How, in each case, where such license is an irrevocable, perpetual, royalty-bearing license, with the right to sublicense, to Develop, Manufacture and Commercialize the Product(s), as the Product(s) exist as of the effective date of such termination, or optimized versions thereof that are Products.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__License Grant_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Aimmune hereby grants to Xencor an exclusive license under and with respect to Aimmune Patents, and a non-exclusive license under and with respect to Aimmune Know-How, in each case, where such license is an irrevocable, perpetual, royalty-bearing license, with the right to sublicense, to Develop, Manufacture and Commercialize the Product(s), as the Product(s) exist as of the effective date of such termination, or optimized versions thereof that are Products.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the terms and conditions of this Agreement, Xencor hereby grants to Aimmune during the Term an exclusive, worldwide, payment-bearing license under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents, and a non-exclusive, payment bearing license under and with respect to Xencor Know-How, in each case, with the right to sublicense solely in accordance with Section 2.3.2, solely to Develop, Manufacture and Commercialize the Product in and for the Licensed Field; provided that notwithstanding the foregoing, Xencor shall retain the right under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents to the extent necessary to perform its obligations under this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__License Grant_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the terms and conditions of this Agreement, Xencor hereby grants to Aimmune during the Term an exclusive, worldwide, payment-bearing license under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents, and a non-exclusive, payment bearing license under and with respect to Xencor Know-How, in each case, with the right to sublicense solely in accordance with Section 2.3.2, solely to Develop, Manufacture and Commercialize the Product in and for the Licensed Field; provided that notwithstanding the foregoing, Xencor shall retain the right under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents to the extent necessary to perform its obligations under this Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__License Grant_2",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Aimmune hereby covenants and agrees that it shall not (and shall cause the other Aimmune Agreement Entities not to), either directly or indirectly,",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Non-Transferable License_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "Subject to the terms and conditions of this Agreement, Xencor hereby grants to Aimmune during the Term an exclusive, worldwide, payment-bearing license under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents, and a non-exclusive, payment bearing license under and with respect to Xencor Know-How, in each case, with the right to sublicense solely in accordance with Section 2.3.2, solely to Develop, Manufacture and Commercialize the Product in and for the Licensed Field; provided that notwithstanding the foregoing, Xencor shall retain the right under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents to the extent necessary to perform its obligations under this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Non-Transferable License_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "Subject to the terms and conditions of this Agreement, Xencor hereby grants to Aimmune during the Term an exclusive, worldwide, payment-bearing license under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents, and a non-exclusive, payment bearing license under and with respect to Xencor Know-How, in each case, with the right to sublicense solely in accordance with Section 2.3.2, solely to Develop, Manufacture and Commercialize the Product in and for the Licensed Field; provided that notwithstanding the foregoing, Xencor shall retain the right under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents to the extent necessary to perform its obligations under this Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Affiliate License-Licensor_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor?Â ",
      "answer_text": "Subject to the terms and conditions of this Agreement, Xencor hereby grants to Aimmune during the Term an exclusive, worldwide, payment-bearing license under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents, and a non-exclusive, payment bearing license under and with respect to Xencor Know-How, in each case, with the right to sublicense solely in accordance with Section 2.3.2, solely to Develop, Manufacture and Commercialize the Product in and for the Licensed Field; provided that notwithstanding the foregoing, Xencor shall retain the right under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents to the extent necessary to perform its obligations under this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Affiliate License-Licensor_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor?Â ",
      "answer_text": "Subject to the terms and conditions of this Agreement, Xencor hereby grants to Aimmune during the Term an exclusive, worldwide, payment-bearing license under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents, and a non-exclusive, payment bearing license under and with respect to Xencor Know-How, in each case, with the right to sublicense solely in accordance with Section 2.3.2, solely to Develop, Manufacture and Commercialize the Product in and for the Licensed Field; provided that notwithstanding the foregoing, Xencor shall retain the right under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents to the extent necessary to perform its obligations under this Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Affiliate License-Licensor_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor?Â ",
      "answer_text": "\"Xencor Know-How\" means any and all Know-How, whether or not patented or patentable, (i) to the extent Controlled by Xencor or its Affiliates as of the Effective Date, or, if transferred to Aimmune thereafter during the Term of this Agreement, and that is necessary in connection with the Development, Manufacture, Commercialization or other use of the Antibody or Product or (ii) constituting a Xencor Invention. Notwithstanding the foregoing, in all cases, Xencor Know-How does not include (a) [***], (b) [***], (c) [***], (d) [***], (e) [***], or (f) [***].",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.3",
          "bbox": [
            2835.0,
            283.0,
            3056.0,
            322.0
          ],
          "confidence": 0.9996052384376526
        },
        {
          "text": "[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material",
          "bbox": [
            279.0,
            389.0,
            3034.0,
            435.0
          ],
          "confidence": 0.9883718490600586
        },
        {
          "text": "and would likely cause competitive harm to the registrant if publicly disclosed..",
          "bbox": [
            274.0,
            446.0,
            1718.0,
            490.0
          ],
          "confidence": 0.9940534234046936
        },
        {
          "text": "Execution Copy",
          "bbox": [
            2751.0,
            524.0,
            3056.0,
            576.0
          ],
          "confidence": 0.9972357749938965
        },
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ],
          "confidence": 0.9972044229507446
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ],
          "confidence": 0.9708194732666016
        },
        {
          "text": "BY AND BETWEEN",
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ],
          "confidence": 0.9989999532699585
        },
        {
          "text": "XENCOR, INC.",
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ],
          "confidence": 0.9703187942504883
        },
        {
          "text": "AND",
          "bbox": [
            1622.0,
            967.0,
            1716.0,
            1007.0
          ],
          "confidence": 0.9991505742073059
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ],
          "confidence": 0.9924952983856201
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9902650713920593
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 0,
          "bbox": [
            986.0,
            641.0,
            2351.0,
            678.0
          ]
        },
        {
          "text": "DATED AS OF FEBRUARY 4, 2020",
          "page": 0,
          "bbox": [
            1343.0,
            724.0,
            1992.0,
            760.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1486.0,
            808.0,
            1851.0,
            839.0
          ]
        },
        {
          "text": "XENCOR, INC.",
          "page": 0,
          "bbox": [
            1522.0,
            888.0,
            1809.0,
            925.0
          ]
        },
        {
          "text": "AIMMUNE THERAPEUTICS, INC",
          "page": 0,
          "bbox": [
            1350.0,
            1049.0,
            1981.0,
            1085.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Affiliate License-Licensor_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor?Â ",
      "answer_text": "\"Xencor Know-How\" means any and all Know-How, whether or not patented or patentable, (i) to the extent Controlled by Xencor or its Affiliates as of the Effective Date, or, if transferred to Aimmune thereafter during the Term of this Agreement, and that is necessary in connection with the Development, Manufacture, Commercialization or other use of the Antibody or Product or (ii) constituting a Xencor Invention. Notwithstanding the foregoing, in all cases, Xencor Know-How does not include (a) [***], (b) [***], (c) [***], (d) [***], (e) [***], or (f) [***].",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Affiliate License-Licensee_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "Aimmune shall [***] the right (but not the obligation) to sublicense the rights granted to it under Section 2.1 to its Affiliates or Third Parties (each, a \"Sublicensee\"); provided, however, that Aimmune shall remain responsible for the performance by any of its direct and indirect Sublicensees and shall cause its direct and indirect Sublicensees to comply with the applicable provisions of this Agreement in connection with such performance.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Affiliate License-Licensee_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "Aimmune shall [***] the right (but not the obligation) to sublicense the rights granted to it under Section 2.1 to its Affiliates or Third Parties (each, a \"Sublicensee\"); provided, however, that Aimmune shall remain responsible for the performance by any of its direct and indirect Sublicensees and shall cause its direct and indirect Sublicensees to comply with the applicable provisions of this Agreement in connection with such performance.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Irrevocable Or Perpetual License_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain aÂ  license grant that is irrevocable or perpetual?",
      "answer_text": "Aimmune hereby grants to Xencor an exclusive license under and with respect to Aimmune Patents, and a non-exclusive license under and with respect to Aimmune Know-How, in each case, where such license is an irrevocable, perpetual, royalty-bearing license, with the right to sublicense, to Develop, Manufacture and Commercialize the Product(s), as the Product(s) exist as of the effective date of such termination, or optimized versions thereof that are Products.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Irrevocable Or Perpetual License_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain aÂ  license grant that is irrevocable or perpetual?",
      "answer_text": "Aimmune hereby grants to Xencor an exclusive license under and with respect to Aimmune Patents, and a non-exclusive license under and with respect to Aimmune Know-How, in each case, where such license is an irrevocable, perpetual, royalty-bearing license, with the right to sublicense, to Develop, Manufacture and Commercialize the Product(s), as the Product(s) exist as of the effective date of such termination, or optimized versions thereof that are Products.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Post-Termination Services_2",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Upon expiration of this Agreement with respect to a Product in a country, the licenses granted to Aimmune pursuant to this Agreement shall continue in full force and effect on a fully-paid basis.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "ending on the last day of the [***] following the effective date of such termination, to sell any inventory of Product affected by such termination that remains on hand as of the effective date of the termination, so long as Aimmune pays to Xencor all amounts payable hereunder (including milestones) applicable to said subsequent sales, as applicable, in accordance with the terms and conditions set forth in this Agreement and otherwise complies with the terms set forth in this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Post-Termination Services_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "ending on the last day of the [***] following the effective date of such termination, to sell any inventory of Product affected by such termination that remains on hand as of the effective date of the termination, so long as Aimmune pays to Xencor all amounts payable hereunder (including milestones) applicable to said subsequent sales, as applicable, in accordance with the terms and conditions set forth in this Agreement and otherwise complies with the terms set forth in this Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Upon the termination of this Agreement:\n\n14.1.1 all rights and licenses granted to Aimmune hereunder shall immediately terminate and be of no further force and effect and Aimmune shall cease Developing, Commercializing, Manufacturing and Packaging and Labeling such Product in and for all applicable countries; provided, that Aimmune and its Affiliates will be entitled, during the period",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Post-Termination Services_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Upon the termination of this Agreement:\n\n14.1.1 all rights and licenses granted to Aimmune hereunder shall immediately terminate and be of no further force and effect and Aimmune shall cease Developing, Commercializing, Manufacturing and Packaging and Labeling such Product in and for all applicable countries; provided, that Aimmune and its Affiliates will be entitled, during the period",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Audit Rights_9",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Xencor shall bear the full cost of such audit unless such audit discloses an underpayment of more than [***] percent ([***]%) of the payments due under this Agreement, in which case, [***].",
      "page_number": 9,
      "words": [
        {
          "text": "1.50 \"Net Sales' means, with respect to a Product, the gross amount invoiced for sales of a Product by a Selling Party to Third Parties for end use..",
          "bbox": [
            390.0,
            296.0,
            3041.0,
            333.0
          ],
          "confidence": 0.9826177954673767
        },
        {
          "text": "less the following deductions from such gross amounts to the extent attributable to such Product and to the extent actually incurred, allowed, accrued or",
          "bbox": [
            277.0,
            351.0,
            3032.0,
            387.0
          ],
          "confidence": 0.9879276156425476
        },
        {
          "text": "specifically allocated:",
          "bbox": [
            277.0,
            400.0,
            667.0,
            448.0
          ],
          "confidence": 0.9829296469688416
        },
        {
          "text": "(a) credits or allowances actually granted for damaged Product, returns or rejections of Product, price adjustments and billing errors;",
          "bbox": [
            636.0,
            484.0,
            3023.0,
            528.0
          ],
          "confidence": 0.9899289608001709
        },
        {
          "text": "(b) governmental and other rebates (or equivalents thereof) granted to managed health care organizations, pharmacy benefit.",
          "bbox": [
            638.0,
            592.0,
            2878.0,
            638.0
          ],
          "confidence": 0.9919953346252441
        },
        {
          "text": "managers (or equivalents thereof), federal, state, provincial, local and other governments, their agencies and purchasers and reimbursers or to trade",
          "bbox": [
            272.0,
            647.0,
            2936.0,
            693.0
          ],
          "confidence": 0.9955980777740479
        },
        {
          "text": "customers;",
          "bbox": [
            276.0,
            709.0,
            480.0,
            746.0
          ],
          "confidence": 0.9991086721420288
        },
        {
          "text": "(c) normal and customary trade, cash and quantity discounts, allowances and credits actually allowed or paid;.",
          "bbox": [
            642.0,
            815.0,
            2619.0,
            852.0
          ],
          "confidence": 0.9783806800842285
        },
        {
          "text": "(d) payments made as part of a Co-pay Program for a Product; and.",
          "bbox": [
            638.0,
            917.0,
            1834.0,
            965.0
          ],
          "confidence": 0.9874099493026733
        },
        {
          "text": "(e) sales taxes, VAT taxes and other taxes directly linked to the sales of Product;.",
          "bbox": [
            640.0,
            1029.0,
            2072.0,
            1071.0
          ],
          "confidence": 0.9751432538032532
        },
        {
          "text": "all as determined in accordance with IFRS on a basis consistent with the Selling Party's annual audited financial statements.",
          "bbox": [
            279.0,
            1138.0,
            2507.0,
            1175.0
          ],
          "confidence": 0.9930660128593445
        },
        {
          "text": "Net Sales shall not include sales to Affiliates, Sublicensees or contractors engaged by Aimmune to Develop, Manufacture, or Commercialize the",
          "bbox": [
            386.0,
            1244.0,
            2985.0,
            1290.0
          ],
          "confidence": 0.9849533438682556
        },
        {
          "text": "Product, solely to the extent that such Affiliate, Sublicensees or contractor purchasing the Product resells such Product to a Third Party. However,.",
          "bbox": [
            279.0,
            1303.0,
            2920.0,
            1345.0
          ],
          "confidence": 0.98587566614151
        },
        {
          "text": "subsequent sales of Product by such Aimmune Affiliates, Sublicensees or contractors to a Third Party shall be included in the Net Sales when sold in the",
          "bbox": [
            277.0,
            1356.0,
            3047.0,
            1396.0
          ],
          "confidence": 0.9926484823226929
        },
        {
          "text": "market for end-user use..",
          "bbox": [
            275.0,
            1411.0,
            712.0,
            1451.0
          ],
          "confidence": 0.9859169125556946
        },
        {
          "text": "Further, any use, supply or provision of Product by Aimmune or Aimmune Agreement Entities at no cost or at a de minimis cost not to exceed",
          "bbox": [
            388.0,
            1520.0,
            2953.0,
            1562.0
          ],
          "confidence": 0.9953159689903259
        },
        {
          "text": "[***] percent ([***]%) of the fully burdened cost thereof (i) in connection with patient assistance programs, (ii) for charitable or promotional purposes,.",
          "bbox": [
            279.0,
            1575.0,
            3009.0,
            1617.0
          ],
          "confidence": 0.9941624999046326
        },
        {
          "text": "(iii) for preclinical, clinical, regulatory or governmental purposes, or compassionate use or other similar programs, or (iv) for tests or studies reasonably",
          "bbox": [
            279.0,
            1630.0,
            2996.0,
            1672.0
          ],
          "confidence": 0.9983571171760559
        },
        {
          "text": "necessary to comply with any Applicable Law, regulation or request by a Regulatory Authority shall not be included in Net Sales of Product. Sale or",
          "bbox": [
            274.0,
            1681.0,
            2954.0,
            1727.0
          ],
          "confidence": 0.9935613870620728
        },
        {
          "text": "transfer of Products among the Aimmune Agreement Entities shall not result in any Net Sales, in which case Net Sales shall be based only on any",
          "bbox": [
            274.0,
            1734.0,
            2904.0,
            1782.0
          ],
          "confidence": 0.9948053956031799
        },
        {
          "text": "subsequent sales or dispositions to a Third Party; provided that the Aimmune Agreement Entity is not an end user.",
          "bbox": [
            279.0,
            1796.0,
            2358.0,
            1833.0
          ],
          "confidence": 0.9964967966079712
        },
        {
          "text": "In no event shall any particular amount identified above be deducted more than once in calculating Net Sales (i.e., no \"double counting\" of",
          "bbox": [
            388.0,
            1900.0,
            2904.0,
            1944.0
          ],
          "confidence": 0.9832816123962402
        },
        {
          "text": "reductions).",
          "bbox": [
            277.0,
            1957.0,
            491.0,
            1995.0
          ],
          "confidence": 0.992103099822998
        },
        {
          "text": "In the event that Product is sold as part of a financial bundle with other products or included in financial package deals to customers and in such.",
          "bbox": [
            388.0,
            2065.0,
            3003.0,
            2107.0
          ],
          "confidence": 0.9937145113945007
        },
        {
          "text": "case, the price of Product relevant for the calculation of Net Sales will be the average invoiced sales price of Product in the preceding Calendar Quarter",
          "bbox": [
            279.0,
            2120.0,
            2994.0,
            2162.0
          ],
          "confidence": 0.9940312504768372
        },
        {
          "text": "sold separately less the average discount of all products sold as part of such bundle or package..",
          "bbox": [
            277.0,
            2173.0,
            2016.0,
            2218.0
          ],
          "confidence": 0.9856414198875427
        },
        {
          "text": "8",
          "bbox": [
            1653.0,
            2229.0,
            1682.0,
            2268.0
          ],
          "confidence": 0.9882963299751282
        },
        {
          "text": "SourCe: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9914016127586365
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Audit Rights_2",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Prompt adjustments shall be made by the Parties to reflect the results of such audit.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Audit Rights_2",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "An audit under this Section 8.4 shall not occur more than [***] in any Calendar Year, except in the case of any subsequent \"for cause\" audit.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Audit Rights_3",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "The audit shall be limited to pertinent records kept by Aimmune and its Affiliates and Sublicensees for any year ending not more than [***] ([***]) months prior to the date of the written notice.",
      "page_number": 3,
      "words": [
        {
          "text": "1.3 \"Aimmune Agreement Entities\"' means Aimmune's Affiliates and Sublicensees (excluding distributors)",
          "bbox": [
            390.0,
            292.0,
            2338.0,
            336.0
          ],
          "confidence": 0.9935991764068604
        },
        {
          "text": "1.4 \"Aimmune Common Stock'' means Aimmune's common stock, par value $0.0001 per share",
          "bbox": [
            391.0,
            402.0,
            2103.0,
            442.0
          ],
          "confidence": 0.981459379196167
        },
        {
          "text": "1.5 \"Aimmune Field' means the field of [***].",
          "bbox": [
            388.0,
            508.0,
            1233.0,
            554.0
          ],
          "confidence": 0.9712823033332825
        },
        {
          "text": "1.6 \"Aimmune Invention' means an Invention that is Invented, solely or jointly with a Third Party, by or on behalf of Aimmune or its Affiliates.",
          "bbox": [
            388.0,
            618.0,
            2974.0,
            663.0
          ],
          "confidence": 0.9865084886550903
        },
        {
          "text": "1.7 \"Aimmune Know-How\" means any and all Know-How, whether or not patented or patentable, that is Controlled by Aimmune or its Affiliates as",
          "bbox": [
            390.0,
            729.0,
            3047.0,
            769.0
          ],
          "confidence": 0.9896785020828247
        },
        {
          "text": "of the Effective Date or at any time during the Term that is necessary or reasonably useful in connection with the Development, Manufacture,",
          "bbox": [
            275.0,
            782.0,
            2831.0,
            828.0
          ],
          "confidence": 0.9936000108718872
        },
        {
          "text": "Commercialization or other use of the Antibody or Product.",
          "bbox": [
            277.0,
            839.0,
            1343.0,
            879.0
          ],
          "confidence": 0.9995146989822388
        },
        {
          "text": "1.8 \"Aimmune Patent'' means any Patent that (i) (a) is Controlled by Aimmune (or its Affiliates) as of the Effective Date or comes under the",
          "bbox": [
            388.0,
            945.0,
            2913.0,
            989.0
          ],
          "confidence": 0.9862771034240723
        },
        {
          "text": "Control of Aimmune (or its Affiliates) during the Term (other than as a result of the licenses granted by Xencor to Aimmune under this Agreement) and",
          "bbox": [
            277.0,
            1003.0,
            3003.0,
            1045.0
          ],
          "confidence": 0.9990835785865784
        },
        {
          "text": "(b) that would be infringed by the Development, Manufacture, Commercialization or use of the Antibody or Product or that claims or Covers Aimmune",
          "bbox": [
            283.0,
            1060.0,
            2989.0,
            1096.0
          ],
          "confidence": 0.9943405389785767
        },
        {
          "text": "Know-How, or (ii) is an Aimmune Collaboration Patent.",
          "bbox": [
            281.0,
            1117.0,
            1263.0,
            1148.0
          ],
          "confidence": 0.9957587122917175
        },
        {
          "text": "1.9 \"Aimmune Technology' means Aimmune Know-How and Aimmune Patents.",
          "bbox": [
            388.0,
            1217.0,
            1851.0,
            1261.0
          ],
          "confidence": 0.9875858426094055
        },
        {
          "text": "1.10 \"Antibody' means Xencor's humanized antibody known as XmAb7195 having the sequence listed in Schedule 1.10.",
          "bbox": [
            390.0,
            1328.0,
            2574.0,
            1371.0
          ],
          "confidence": 0.9897436499595642
        },
        {
          "text": "1.11 \"Anti-Corruption Laws\" means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, as well as",
          "bbox": [
            388.0,
            1434.0,
            2889.0,
            1478.0
          ],
          "confidence": 0.9914922714233398
        },
        {
          "text": "Applicable Law related to the prevention of fraud, racketeering, money laundering or terrorism.",
          "bbox": [
            281.0,
            1495.0,
            1988.0,
            1537.0
          ],
          "confidence": 0.9964950680732727
        },
        {
          "text": "1.12 \"Applicable Law\"' means any applicable United States federal, state or local or foreign or multinational law, statute, standard, ordinance, code,",
          "bbox": [
            386.0,
            1599.0,
            3040.0,
            1645.0
          ],
          "confidence": 0.9866900444030762
        },
        {
          "text": "rule, regulation, resolution or promulgation, or any order, writ, judgment, injunction, decree, stipulation, ruling, determination or award entered by or with",
          "bbox": [
            276.0,
            1657.0,
            3029.0,
            1699.0
          ],
          "confidence": 0.9940216541290283
        },
        {
          "text": "any Governmental Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force",
          "bbox": [
            277.0,
            1712.0,
            3052.0,
            1754.0
          ],
          "confidence": 0.9971250891685486
        },
        {
          "text": "or effect of law. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall be deemed to include all then-",
          "bbox": [
            274.0,
            1763.0,
            2976.0,
            1809.0
          ],
          "confidence": 0.9982315897941589
        },
        {
          "text": "current amendments thereto or any replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, order, writ, judgment",
          "bbox": [
            276.0,
            1822.0,
            2982.0,
            1864.0
          ],
          "confidence": 0.9947020411491394
        },
        {
          "text": "injunction, decree, stipulation, ruling, or determination thereto.",
          "bbox": [
            277.0,
            1875.0,
            1405.0,
            1915.0
          ],
          "confidence": 0.9998493790626526
        },
        {
          "text": "2",
          "bbox": [
            1651.0,
            1930.0,
            1682.0,
            1966.0
          ],
          "confidence": 0.9919590950012207
        },
        {
          "text": "SourCe: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9840355515480042
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Audit Rights_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Xencor shall have the right, upon [***] ([***]) days' prior written notice to Aimmune, to cause an independent, certified international public accounting firm reasonably acceptable to Aimmune or reasonably acceptable to its Affiliates or Sublicensees, as applicable, to audit such records during Aimmune's, or its Affiliate's or Sublicensees', as applicable, normal business hours to confirm the number of Product units sold, the gross sales and Net Sales of Product, the royalties payable, the method used to calculate the royalties payable, and the exchange rates used in accordance with Section 8.2",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Audit Rights_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Xencor shall have the right, upon [***] ([***]) days' prior written notice to Aimmune, to cause an independent, certified international public accounting firm reasonably acceptable to Aimmune or reasonably acceptable to its Affiliates or Sublicensees, as applicable, to audit such records during Aimmune's, or its Affiliate's or Sublicensees', as applicable, normal business hours to confirm the number of Product units sold, the gross sales and Net Sales of Product, the royalties payable, the method used to calculate the royalties payable, and the exchange rates used in accordance with Section 8.2",
      "page_number": 3,
      "words": [
        {
          "text": "1.3 \"Aimmune Agreement Entities\"' means Aimmune's Affiliates and Sublicensees (excluding distributors)",
          "bbox": [
            390.0,
            292.0,
            2338.0,
            336.0
          ],
          "confidence": 0.9935991764068604
        },
        {
          "text": "1.4 \"Aimmune Common Stock'' means Aimmune's common stock, par value $0.0001 per share",
          "bbox": [
            391.0,
            402.0,
            2103.0,
            442.0
          ],
          "confidence": 0.981459379196167
        },
        {
          "text": "1.5 \"Aimmune Field' means the field of [***].",
          "bbox": [
            388.0,
            508.0,
            1233.0,
            554.0
          ],
          "confidence": 0.9712823033332825
        },
        {
          "text": "1.6 \"Aimmune Invention' means an Invention that is Invented, solely or jointly with a Third Party, by or on behalf of Aimmune or its Affiliates.",
          "bbox": [
            388.0,
            618.0,
            2974.0,
            663.0
          ],
          "confidence": 0.9865084886550903
        },
        {
          "text": "1.7 \"Aimmune Know-How\" means any and all Know-How, whether or not patented or patentable, that is Controlled by Aimmune or its Affiliates as",
          "bbox": [
            390.0,
            729.0,
            3047.0,
            769.0
          ],
          "confidence": 0.9896785020828247
        },
        {
          "text": "of the Effective Date or at any time during the Term that is necessary or reasonably useful in connection with the Development, Manufacture,",
          "bbox": [
            275.0,
            782.0,
            2831.0,
            828.0
          ],
          "confidence": 0.9936000108718872
        },
        {
          "text": "Commercialization or other use of the Antibody or Product.",
          "bbox": [
            277.0,
            839.0,
            1343.0,
            879.0
          ],
          "confidence": 0.9995146989822388
        },
        {
          "text": "1.8 \"Aimmune Patent'' means any Patent that (i) (a) is Controlled by Aimmune (or its Affiliates) as of the Effective Date or comes under the",
          "bbox": [
            388.0,
            945.0,
            2913.0,
            989.0
          ],
          "confidence": 0.9862771034240723
        },
        {
          "text": "Control of Aimmune (or its Affiliates) during the Term (other than as a result of the licenses granted by Xencor to Aimmune under this Agreement) and",
          "bbox": [
            277.0,
            1003.0,
            3003.0,
            1045.0
          ],
          "confidence": 0.9990835785865784
        },
        {
          "text": "(b) that would be infringed by the Development, Manufacture, Commercialization or use of the Antibody or Product or that claims or Covers Aimmune",
          "bbox": [
            283.0,
            1060.0,
            2989.0,
            1096.0
          ],
          "confidence": 0.9943405389785767
        },
        {
          "text": "Know-How, or (ii) is an Aimmune Collaboration Patent.",
          "bbox": [
            281.0,
            1117.0,
            1263.0,
            1148.0
          ],
          "confidence": 0.9957587122917175
        },
        {
          "text": "1.9 \"Aimmune Technology' means Aimmune Know-How and Aimmune Patents.",
          "bbox": [
            388.0,
            1217.0,
            1851.0,
            1261.0
          ],
          "confidence": 0.9875858426094055
        },
        {
          "text": "1.10 \"Antibody' means Xencor's humanized antibody known as XmAb7195 having the sequence listed in Schedule 1.10.",
          "bbox": [
            390.0,
            1328.0,
            2574.0,
            1371.0
          ],
          "confidence": 0.9897436499595642
        },
        {
          "text": "1.11 \"Anti-Corruption Laws\" means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, as well as",
          "bbox": [
            388.0,
            1434.0,
            2889.0,
            1478.0
          ],
          "confidence": 0.9914922714233398
        },
        {
          "text": "Applicable Law related to the prevention of fraud, racketeering, money laundering or terrorism.",
          "bbox": [
            281.0,
            1495.0,
            1988.0,
            1537.0
          ],
          "confidence": 0.9964950680732727
        },
        {
          "text": "1.12 \"Applicable Law\"' means any applicable United States federal, state or local or foreign or multinational law, statute, standard, ordinance, code,",
          "bbox": [
            386.0,
            1599.0,
            3040.0,
            1645.0
          ],
          "confidence": 0.9866900444030762
        },
        {
          "text": "rule, regulation, resolution or promulgation, or any order, writ, judgment, injunction, decree, stipulation, ruling, determination or award entered by or with",
          "bbox": [
            276.0,
            1657.0,
            3029.0,
            1699.0
          ],
          "confidence": 0.9940216541290283
        },
        {
          "text": "any Governmental Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force",
          "bbox": [
            277.0,
            1712.0,
            3052.0,
            1754.0
          ],
          "confidence": 0.9971250891685486
        },
        {
          "text": "or effect of law. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall be deemed to include all then-",
          "bbox": [
            274.0,
            1763.0,
            2976.0,
            1809.0
          ],
          "confidence": 0.9982315897941589
        },
        {
          "text": "current amendments thereto or any replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, order, writ, judgment",
          "bbox": [
            276.0,
            1822.0,
            2982.0,
            1864.0
          ],
          "confidence": 0.9947020411491394
        },
        {
          "text": "injunction, decree, stipulation, ruling, or determination thereto.",
          "bbox": [
            277.0,
            1875.0,
            1405.0,
            1915.0
          ],
          "confidence": 0.9998493790626526
        },
        {
          "text": "2",
          "bbox": [
            1651.0,
            1930.0,
            1682.0,
            1966.0
          ],
          "confidence": 0.9919590950012207
        },
        {
          "text": "SourCe: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9840355515480042
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Uncapped Liability_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a partyâs liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
      "answer_text": "NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 11.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 11.1 or 11.2, OR DAMAGES AVAILABLE FOR A PARTY'S BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 12.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Uncapped Liability_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a partyâs liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
      "answer_text": "NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 11.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 11.1 or 11.2, OR DAMAGES AVAILABLE FOR A PARTY'S BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 12.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Cap On Liability_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a partyâs obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY LOST PROFITS, OR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING,",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Cap On Liability_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a partyâs obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY LOST PROFITS, OR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING,",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Cap On Liability_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a partyâs obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY LOST PROFITS, OR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 11.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 11.1 or 11.2, OR DAMAGES AVAILABLE FOR A PARTY'S BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 12.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Cap On Liability_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a partyâs obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY LOST PROFITS, OR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 11.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 11.1 or 11.2, OR DAMAGES AVAILABLE FOR A PARTY'S BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 12.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Insurance_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Aimmune shall procure and maintain insurance, including clinical trials insurance and product liability insurance, adequate to cover its obligations hereunder and which is consistent with normal business practices of prudent companies similarly situated at all times during which the Product is being clinically tested in human subjects or commercially distributed or sold by Aimmune pursuant to this Agreement; provided, that any such clinical trials insurance coverage shall, prior to the First Commercial Sale of a Product, in no event be less than [***] Dollars ($[***]) per loss occurrence, and product liability insurance coverage shall, after such First Commercial Sale, in no event be less than [***] Dollars ($[***]) per loss occurrence.",
      "page_number": 3,
      "words": [
        {
          "text": "1.3 \"Aimmune Agreement Entities\"' means Aimmune's Affiliates and Sublicensees (excluding distributors)",
          "bbox": [
            390.0,
            292.0,
            2338.0,
            336.0
          ],
          "confidence": 0.9935991764068604
        },
        {
          "text": "1.4 \"Aimmune Common Stock'' means Aimmune's common stock, par value $0.0001 per share",
          "bbox": [
            391.0,
            402.0,
            2103.0,
            442.0
          ],
          "confidence": 0.981459379196167
        },
        {
          "text": "1.5 \"Aimmune Field' means the field of [***].",
          "bbox": [
            388.0,
            508.0,
            1233.0,
            554.0
          ],
          "confidence": 0.9712823033332825
        },
        {
          "text": "1.6 \"Aimmune Invention' means an Invention that is Invented, solely or jointly with a Third Party, by or on behalf of Aimmune or its Affiliates.",
          "bbox": [
            388.0,
            618.0,
            2974.0,
            663.0
          ],
          "confidence": 0.9865084886550903
        },
        {
          "text": "1.7 \"Aimmune Know-How\" means any and all Know-How, whether or not patented or patentable, that is Controlled by Aimmune or its Affiliates as",
          "bbox": [
            390.0,
            729.0,
            3047.0,
            769.0
          ],
          "confidence": 0.9896785020828247
        },
        {
          "text": "of the Effective Date or at any time during the Term that is necessary or reasonably useful in connection with the Development, Manufacture,",
          "bbox": [
            275.0,
            782.0,
            2831.0,
            828.0
          ],
          "confidence": 0.9936000108718872
        },
        {
          "text": "Commercialization or other use of the Antibody or Product.",
          "bbox": [
            277.0,
            839.0,
            1343.0,
            879.0
          ],
          "confidence": 0.9995146989822388
        },
        {
          "text": "1.8 \"Aimmune Patent'' means any Patent that (i) (a) is Controlled by Aimmune (or its Affiliates) as of the Effective Date or comes under the",
          "bbox": [
            388.0,
            945.0,
            2913.0,
            989.0
          ],
          "confidence": 0.9862771034240723
        },
        {
          "text": "Control of Aimmune (or its Affiliates) during the Term (other than as a result of the licenses granted by Xencor to Aimmune under this Agreement) and",
          "bbox": [
            277.0,
            1003.0,
            3003.0,
            1045.0
          ],
          "confidence": 0.9990835785865784
        },
        {
          "text": "(b) that would be infringed by the Development, Manufacture, Commercialization or use of the Antibody or Product or that claims or Covers Aimmune",
          "bbox": [
            283.0,
            1060.0,
            2989.0,
            1096.0
          ],
          "confidence": 0.9943405389785767
        },
        {
          "text": "Know-How, or (ii) is an Aimmune Collaboration Patent.",
          "bbox": [
            281.0,
            1117.0,
            1263.0,
            1148.0
          ],
          "confidence": 0.9957587122917175
        },
        {
          "text": "1.9 \"Aimmune Technology' means Aimmune Know-How and Aimmune Patents.",
          "bbox": [
            388.0,
            1217.0,
            1851.0,
            1261.0
          ],
          "confidence": 0.9875858426094055
        },
        {
          "text": "1.10 \"Antibody' means Xencor's humanized antibody known as XmAb7195 having the sequence listed in Schedule 1.10.",
          "bbox": [
            390.0,
            1328.0,
            2574.0,
            1371.0
          ],
          "confidence": 0.9897436499595642
        },
        {
          "text": "1.11 \"Anti-Corruption Laws\" means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, as well as",
          "bbox": [
            388.0,
            1434.0,
            2889.0,
            1478.0
          ],
          "confidence": 0.9914922714233398
        },
        {
          "text": "Applicable Law related to the prevention of fraud, racketeering, money laundering or terrorism.",
          "bbox": [
            281.0,
            1495.0,
            1988.0,
            1537.0
          ],
          "confidence": 0.9964950680732727
        },
        {
          "text": "1.12 \"Applicable Law\"' means any applicable United States federal, state or local or foreign or multinational law, statute, standard, ordinance, code,",
          "bbox": [
            386.0,
            1599.0,
            3040.0,
            1645.0
          ],
          "confidence": 0.9866900444030762
        },
        {
          "text": "rule, regulation, resolution or promulgation, or any order, writ, judgment, injunction, decree, stipulation, ruling, determination or award entered by or with",
          "bbox": [
            276.0,
            1657.0,
            3029.0,
            1699.0
          ],
          "confidence": 0.9940216541290283
        },
        {
          "text": "any Governmental Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force",
          "bbox": [
            277.0,
            1712.0,
            3052.0,
            1754.0
          ],
          "confidence": 0.9971250891685486
        },
        {
          "text": "or effect of law. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall be deemed to include all then-",
          "bbox": [
            274.0,
            1763.0,
            2976.0,
            1809.0
          ],
          "confidence": 0.9982315897941589
        },
        {
          "text": "current amendments thereto or any replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, order, writ, judgment",
          "bbox": [
            276.0,
            1822.0,
            2982.0,
            1864.0
          ],
          "confidence": 0.9947020411491394
        },
        {
          "text": "injunction, decree, stipulation, ruling, or determination thereto.",
          "bbox": [
            277.0,
            1875.0,
            1405.0,
            1915.0
          ],
          "confidence": 0.9998493790626526
        },
        {
          "text": "2",
          "bbox": [
            1651.0,
            1930.0,
            1682.0,
            1966.0
          ],
          "confidence": 0.9919590950012207
        },
        {
          "text": "SourCe: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9840355515480042
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Insurance_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Aimmune shall procure and maintain insurance, including clinical trials insurance and product liability insurance, adequate to cover its obligations hereunder and which is consistent with normal business practices of prudent companies similarly situated at all times during which the Product is being clinically tested in human subjects or commercially distributed or sold by Aimmune pursuant to this Agreement; provided, that any such clinical trials insurance coverage shall, prior to the First Commercial Sale of a Product, in no event be less than [***] Dollars ($[***]) per loss occurrence, and product liability insurance coverage shall, after such First Commercial Sale, in no event be less than [***] Dollars ($[***]) per loss occurrence.",
      "page_number": 4,
      "words": [
        {
          "text": "1.13 \"Baseline Quarter Net Sales\" means, on a country-by-country and Product-by-Product basis, the average cumulative Net Sales of such.",
          "bbox": [
            390.0,
            294.0,
            2960.0,
            336.0
          ],
          "confidence": 0.9905096888542175
        },
        {
          "text": "Product is first commercially sold in such country. For example, if a Generic Product with respect to a given Product is commercially sold in the U.S. for the",
          "bbox": [
            277.0,
            404.0,
            3054.0,
            446.0
          ],
          "confidence": 0.9995065331459045
        },
        {
          "text": "first time on [***], then the Baseline Quarter Net Sales with respect to such Product and U.S. are the cumulative Net Sales of such Product in the U.S..",
          "bbox": [
            277.0,
            457.0,
            2972.0,
            499.0
          ],
          "confidence": 0.9887566566467285
        },
        {
          "text": "during the [***] Calendar Quarters of [***] divided by [***].",
          "bbox": [
            274.0,
            506.0,
            1392.0,
            557.0
          ],
          "confidence": 0.9971281290054321
        },
        {
          "text": "1.14 \"Business Day' means a day other than a Saturday, Sunday, or bank or other public holiday in California..",
          "bbox": [
            388.0,
            618.0,
            2387.0,
            663.0
          ],
          "confidence": 0.9798464179039001
        },
        {
          "text": "that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first full Calendar Quarter thereafter, and (b) the last",
          "bbox": [
            279.0,
            788.0,
            2989.0,
            824.0
          ],
          "confidence": 0.9947574734687805
        },
        {
          "text": "Calendar Quarter of the Term shall end upon the expiration or termination of this Agreement..",
          "bbox": [
            277.0,
            839.0,
            1941.0,
            879.0
          ],
          "confidence": 0.9944866299629211
        },
        {
          "text": "1.16 \"Calendar Year\" means the period beginning on the 1st of January and ending on the 31st of December of the same year; provided, however,",
          "bbox": [
            388.0,
            945.0,
            3036.0,
            990.0
          ],
          "confidence": 0.9919390082359314
        },
        {
          "text": "that (a) the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the same year and (b) the last Calendar Year",
          "bbox": [
            277.0,
            1003.0,
            3023.0,
            1045.0
          ],
          "confidence": 0.9931097626686096
        },
        {
          "text": "of the Term shall commence on January 1 of the Calendar Year in which this Agreement terminates or expires and end on the date of termination or.",
          "bbox": [
            279.0,
            1060.0,
            2909.0,
            1096.0
          ],
          "confidence": 0.9933753609657288
        },
        {
          "text": "expiration of this Agreement..",
          "bbox": [
            279.0,
            1113.0,
            799.0,
            1155.0
          ],
          "confidence": 0.9690341353416443
        },
        {
          "text": "1.17 \"Clinical Trial'' means a clinical trial, including any a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, or Phase IV Clinical",
          "bbox": [
            390.0,
            1221.0,
            3009.0,
            1263.0
          ],
          "confidence": 0.9850612878799438
        },
        {
          "text": "Trial, as the case may be, and as any such trial is defined by an applicable Regulatory Authority..",
          "bbox": [
            275.0,
            1272.0,
            2008.0,
            1319.0
          ],
          "confidence": 0.9939419031143188
        },
        {
          "text": "1.18 \"Co-pay Program\"' means a program to support patient access to a Product whereby the Product manufacturer makes payments to a Third.",
          "bbox": [
            388.0,
            1381.0,
            2987.0,
            1431.0
          ],
          "confidence": 0.9769307374954224
        },
        {
          "text": "Party equal to all or part of the difference between the price of Product prescribed to a patient and the amount such patient pays for such Product",
          "bbox": [
            277.0,
            1438.0,
            2905.0,
            1480.0
          ],
          "confidence": 0.9909642934799194
        },
        {
          "text": "through such patient's insurance plan..",
          "bbox": [
            277.0,
            1491.0,
            972.0,
            1535.0
          ],
          "confidence": 0.9842541217803955
        },
        {
          "text": "1.19 \"Combination Product\"' means any Product containing an Active Ingredient that is not an Antibody. Such Combination Product shall be.",
          "bbox": [
            390.0,
            1601.0,
            2956.0,
            1643.0
          ],
          "confidence": 0.982966959476471
        },
        {
          "text": "either (a) priced and sold in a single package containing such multiple products or (b) packaged separately but sold together for a single price.",
          "bbox": [
            279.0,
            1657.0,
            2840.0,
            1699.0
          ],
          "confidence": 0.9971250295639038
        },
        {
          "text": "1.20 \"Commercialize'' means, with respect to the Product, to promote, market, distribute, sell (and offer for sale or contract to sell), import, export.",
          "bbox": [
            390.0,
            1765.0,
            3027.0,
            1807.0
          ],
          "confidence": 0.983849048614502
        },
        {
          "text": "or otherwise commercially exploit or provide product support for the Product and to conduct activities, other than Development or Manufacturing, in.",
          "bbox": [
            275.0,
            1818.0,
            2967.0,
            1862.0
          ],
          "confidence": 0.9989904165267944
        },
        {
          "text": "preparation for conducting the foregoing activities, including activities to produce commercialization support data and to secure and maintain market.",
          "bbox": [
            275.0,
            1873.0,
            2965.0,
            1919.0
          ],
          "confidence": 0.9971686005592346
        },
        {
          "text": "access and reimbursement. \"Commercializing\" and \"Commercialization'' shall have correlative meanings. For the avoidance of doubt,.",
          "bbox": [
            277.0,
            1932.0,
            2722.0,
            1968.0
          ],
          "confidence": 0.9876875877380371
        },
        {
          "text": "Commercialization does not include Development and Manufacturing.",
          "bbox": [
            275.0,
            1979.0,
            1537.0,
            2028.0
          ],
          "confidence": 0.9999321699142456
        },
        {
          "text": "3",
          "bbox": [
            1651.0,
            2036.0,
            1680.0,
            2076.0
          ],
          "confidence": 0.9936158657073975
        },
        {
          "text": "SourCe: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9858194589614868
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Insurance_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Aimmune shall provide Xencor with written evidence of such insurance prior to commencement of this Agreement and upon expiration of any one coverage. Aimmune shall provide Xencor with written notice at least [***] ([***]) days prior to the cancellation, nonrenewal or material change in such insurance or self-insurance which materially adversely affects the rights of Xencor hereunder.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ],
          "confidence": 0.9993643760681152
        },
        {
          "text": "Page",
          "bbox": [
            2965.0,
            347.0,
            3062.0,
            392.0
          ],
          "confidence": 0.9998871088027954
        },
        {
          "text": "ARTICLE 1 Definitions",
          "bbox": [
            277.0,
            391.0,
            691.0,
            431.0
          ],
          "confidence": 0.9890795946121216
        },
        {
          "text": "1",
          "bbox": [
            3030.0,
            393.0,
            3061.0,
            435.0
          ],
          "confidence": 0.9997724890708923
        },
        {
          "text": "ARTICLE 2 Licenses",
          "bbox": [
            277.0,
            473.0,
            653.0,
            514.0
          ],
          "confidence": 0.9944121241569519
        },
        {
          "text": "13",
          "bbox": [
            3011.0,
            470.0,
            3061.0,
            517.0
          ],
          "confidence": 0.9998679161071777
        },
        {
          "text": "ARTICLE 3 Development",
          "bbox": [
            277.0,
            555.0,
            736.0,
            598.0
          ],
          "confidence": 0.9906356334686279
        },
        {
          "text": "16",
          "bbox": [
            3006.0,
            549.0,
            3064.0,
            602.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "ARTICLE 4 Regulatory",
          "bbox": [
            279.0,
            638.0,
            689.0,
            680.0
          ],
          "confidence": 0.9998478889465332
        },
        {
          "text": "17",
          "bbox": [
            3009.0,
            636.0,
            3061.0,
            682.0
          ],
          "confidence": 0.9999200701713562
        },
        {
          "text": "ARTICLE 5 Commercialization",
          "bbox": [
            279.0,
            722.0,
            816.0,
            758.0
          ],
          "confidence": 0.9997479319572449
        },
        {
          "text": "19",
          "bbox": [
            3011.0,
            716.0,
            3061.0,
            764.0
          ],
          "confidence": 0.9997899532318115
        },
        {
          "text": "ARTICLE 6 Supply",
          "bbox": [
            275.0,
            795.0,
            620.0,
            846.0
          ],
          "confidence": 0.9998118877410889
        },
        {
          "text": "20",
          "bbox": [
            3009.0,
            799.0,
            3061.0,
            844.0
          ],
          "confidence": 0.9993555545806885
        },
        {
          "text": "ARTICLE 7 Payments",
          "bbox": [
            275.0,
            882.0,
            669.0,
            923.0
          ],
          "confidence": 0.9967066645622253
        },
        {
          "text": "21",
          "bbox": [
            3009.0,
            879.0,
            3060.0,
            926.0
          ],
          "confidence": 0.9998354911804199
        },
        {
          "text": "ARTICLE 8 Payment; Records; Audits",
          "bbox": [
            279.0,
            967.0,
            970.0,
            1003.0
          ],
          "confidence": 0.9915331602096558
        },
        {
          "text": "24",
          "bbox": [
            3009.0,
            961.0,
            3061.0,
            1007.0
          ],
          "confidence": 0.9998898506164551
        },
        {
          "text": "ARTICLE 9 Intellectual Property Matters",
          "bbox": [
            279.0,
            1045.0,
            1011.0,
            1087.0
          ],
          "confidence": 0.9995063543319702
        },
        {
          "text": "26",
          "bbox": [
            3009.0,
            1043.0,
            3061.0,
            1089.0
          ],
          "confidence": 0.9998362064361572
        },
        {
          "text": "ARTICLE 10 Representations, Warranties and Covenants; Compliance.",
          "bbox": [
            279.0,
            1129.0,
            1546.0,
            1171.0
          ],
          "confidence": 0.990277111530304
        },
        {
          "text": "31",
          "bbox": [
            3009.0,
            1124.0,
            3060.0,
            1171.0
          ],
          "confidence": 0.999961256980896
        },
        {
          "text": "34",
          "bbox": [
            3005.0,
            1203.0,
            3064.0,
            1255.0
          ],
          "confidence": 0.9998070001602173
        },
        {
          "text": "ARTICLE 11 Indemnification",
          "bbox": [
            281.0,
            1213.0,
            790.0,
            1244.0
          ],
          "confidence": 0.9994386434555054
        },
        {
          "text": "ARTICLE 12 Confidentiality",
          "bbox": [
            277.0,
            1290.0,
            778.0,
            1332.0
          ],
          "confidence": 0.9840336441993713
        },
        {
          "text": "36",
          "bbox": [
            3009.0,
            1288.0,
            3061.0,
            1334.0
          ],
          "confidence": 0.9999332427978516
        },
        {
          "text": "ARTICLE 13 Term and Termination.",
          "bbox": [
            277.0,
            1372.0,
            903.0,
            1413.0
          ],
          "confidence": 0.9795197248458862
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1372.0,
            3060.0,
            1414.0
          ],
          "confidence": 0.9993184804916382
        },
        {
          "text": "ARTICLE 14 Effects of Expiration Or Termination",
          "bbox": [
            277.0,
            1455.0,
            1155.0,
            1495.0
          ],
          "confidence": 0.9897091388702393
        },
        {
          "text": "40",
          "bbox": [
            3012.0,
            1455.0,
            3060.0,
            1497.0
          ],
          "confidence": 0.9993410110473633
        },
        {
          "text": "ARTICLE 15 Miscellaneous",
          "bbox": [
            277.0,
            1535.0,
            778.0,
            1575.0
          ],
          "confidence": 0.9956666827201843
        },
        {
          "text": "43",
          "bbox": [
            3012.0,
            1535.0,
            3058.0,
            1579.0
          ],
          "confidence": 0.9998053908348083
        },
        {
          "text": "Schedule 1.10 Antibody",
          "bbox": [
            277.0,
            1617.0,
            709.0,
            1659.0
          ],
          "confidence": 0.9609599709510803
        },
        {
          "text": "50",
          "bbox": [
            3009.0,
            1615.0,
            3061.0,
            1661.0
          ],
          "confidence": 0.9997529983520508
        },
        {
          "text": "Schedule 1.79 Xencor General Patents",
          "bbox": [
            275.0,
            1699.0,
            961.0,
            1738.0
          ],
          "confidence": 0.9986600875854492
        },
        {
          "text": "51",
          "bbox": [
            3009.0,
            1696.0,
            3060.0,
            1743.0
          ],
          "confidence": 0.9998956918716431
        },
        {
          "text": "Schedule 1.81 Xencor Product Specific Patents.",
          "bbox": [
            277.0,
            1782.0,
            1122.0,
            1822.0
          ],
          "confidence": 0.9869087934494019
        },
        {
          "text": "52",
          "bbox": [
            3011.0,
            1778.0,
            3061.0,
            1826.0
          ],
          "confidence": 0.9999735355377197
        },
        {
          "text": "Schedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data",
          "bbox": [
            275.0,
            1864.0,
            1657.0,
            1904.0
          ],
          "confidence": 0.9993235468864441
        },
        {
          "text": "53",
          "bbox": [
            3012.0,
            1860.0,
            3058.0,
            1904.0
          ],
          "confidence": 0.9999399781227112
        },
        {
          "text": "Schedule 6.1 Initial Product Supply",
          "bbox": [
            275.0,
            1941.0,
            906.0,
            1990.0
          ],
          "confidence": 0.9939813017845154
        },
        {
          "text": "54",
          "bbox": [
            3011.0,
            1941.0,
            3061.0,
            1988.0
          ],
          "confidence": 0.9999373555183411
        },
        {
          "text": "Schedule 10.2.6 Exceptions",
          "bbox": [
            277.0,
            2026.0,
            763.0,
            2067.0
          ],
          "confidence": 0.9993525743484497
        },
        {
          "text": "55",
          "bbox": [
            3012.0,
            2027.0,
            3058.0,
            2070.0
          ],
          "confidence": 0.9999149441719055
        },
        {
          "text": "Schedule 12.2 Initial Press Release.",
          "bbox": [
            275.0,
            2109.0,
            894.0,
            2147.0
          ],
          "confidence": 0.9885552525520325
        },
        {
          "text": "56",
          "bbox": [
            3012.0,
            2107.0,
            3060.0,
            2149.0
          ],
          "confidence": 0.9999004006385803
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4437.0,
            1426.0,
            4479.0
          ],
          "confidence": 0.9923546314239502
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1445.0,
            292.0,
            1887.0,
            329.0
          ]
        }
      ]
    },
    {
      "id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement__Insurance_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Aimmune shall provide Xencor with written evidence of such insurance prior to commencement of this Agreement and upon expiration of any one coverage. Aimmune shall provide Xencor with written notice at least [***] ([***]) days prior to the cancellation, nonrenewal or material change in such insurance or self-insurance which materially adversely affects the rights of Xencor hereunder.",
      "page_number": 2,
      "words": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ],
          "confidence": 0.9904011487960815
        },
        {
          "text": "This License, Development and Commercialization Agreement (this \"Agreement'), dated as of February 4, 2020 (the \"Effective Date'), is made by",
          "bbox": [
            388.0,
            400.0,
            3025.0,
            446.0
          ],
          "confidence": 0.9820835590362549
        },
        {
          "text": "and between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune'). Xencor and Aimmune are sometimes referred to herein.",
          "bbox": [
            279.0,
            460.0,
            2833.0,
            497.0
          ],
          "confidence": 0.9790953397750854
        },
        {
          "text": "individually as a \"Party\" and collectively as the \"Parties\".",
          "bbox": [
            279.0,
            512.0,
            1349.0,
            552.0
          ],
          "confidence": 0.9836345314979553
        },
        {
          "text": "RECITALS",
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ],
          "confidence": 0.9996452331542969
        },
        {
          "text": "WheREAs, Xencor has developed the Antibody (as defined below);.",
          "bbox": [
            390.0,
            778.0,
            1622.0,
            828.0
          ],
          "confidence": 0.9605622291564941
        },
        {
          "text": "WHEREAs, Aimmune is interested in further developing and commercializing the Antibody; and",
          "bbox": [
            390.0,
            890.0,
            2122.0,
            936.0
          ],
          "confidence": 0.984605073928833
        },
        {
          "text": "WHeREAs, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture.",
          "bbox": [
            388.0,
            1000.0,
            3047.0,
            1045.0
          ],
          "confidence": 0.9863539934158325
        },
        {
          "text": "and commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions.",
          "bbox": [
            277.0,
            1056.0,
            2996.0,
            1096.0
          ],
          "confidence": 0.9928613901138306
        },
        {
          "text": "set forth below.",
          "bbox": [
            277.0,
            1113.0,
            555.0,
            1149.0
          ],
          "confidence": 0.9998562335968018
        },
        {
          "text": "No w THEReFoRE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,",
          "bbox": [
            386.0,
            1221.0,
            3000.0,
            1263.0
          ],
          "confidence": 0.9747233986854553
        },
        {
          "text": "and for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:.",
          "bbox": [
            279.0,
            1275.0,
            2400.0,
            1318.0
          ],
          "confidence": 0.9916032552719116
        },
        {
          "text": "ARTICLE 1",
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ],
          "confidence": 0.9662262797355652
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ],
          "confidence": 0.9990710616111755
        },
        {
          "text": "As used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined",
          "bbox": [
            388.0,
            1599.0,
            2967.0,
            1643.0
          ],
          "confidence": 0.9987982511520386
        },
        {
          "text": "elsewhere in this Agreement:",
          "bbox": [
            279.0,
            1656.0,
            803.0,
            1696.0
          ],
          "confidence": 0.9998318552970886
        },
        {
          "text": "1.1 \"Active Ingredient\"' means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a",
          "bbox": [
            388.0,
            1738.0,
            3030.0,
            1780.0
          ],
          "confidence": 0.9963456392288208
        },
        {
          "text": "drug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which",
          "bbox": [
            277.0,
            1791.0,
            2965.0,
            1835.0
          ],
          "confidence": 0.9953883290290833
        },
        {
          "text": "such substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment.",
          "bbox": [
            275.0,
            1846.0,
            3038.0,
            1889.0
          ],
          "confidence": 0.9918282628059387
        },
        {
          "text": "or prevention of disease or to affect the structure or function of the body..",
          "bbox": [
            279.0,
            1902.0,
            1602.0,
            1944.0
          ],
          "confidence": 0.9857415556907654
        },
        {
          "text": "1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with.",
          "bbox": [
            388.0,
            2010.0,
            3014.0,
            2054.0
          ],
          "confidence": 0.9918243885040283
        },
        {
          "text": "such person; provided, that, for purposes of this definition, \"control'' (including, with correlative meanings, the terms \"controlled by' and \"under",
          "bbox": [
            279.0,
            2069.0,
            2905.0,
            2105.0
          ],
          "confidence": 0.9894629716873169
        },
        {
          "text": "common control with'), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the.",
          "bbox": [
            275.0,
            2120.0,
            2909.0,
            2160.0
          ],
          "confidence": 0.9905549883842468
        },
        {
          "text": "direction of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the",
          "bbox": [
            277.0,
            2175.0,
            2938.0,
            2217.0
          ],
          "confidence": 0.9919141530990601
        },
        {
          "text": "ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\"' means.",
          "bbox": [
            277.0,
            2229.0,
            3020.0,
            2271.0
          ],
          "confidence": 0.9890745878219604
        },
        {
          "text": "mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a",
          "bbox": [
            274.0,
            2284.0,
            2958.0,
            2326.0
          ],
          "confidence": 0.9958456754684448
        },
        {
          "text": "person' as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated",
          "bbox": [
            281.0,
            2337.0,
            2884.0,
            2379.0
          ],
          "confidence": 0.9898776412010193
        },
        {
          "text": "thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government..",
          "bbox": [
            279.0,
            2396.0,
            2447.0,
            2432.0
          ],
          "confidence": 0.9923872351646423
        },
        {
          "text": "1",
          "bbox": [
            1653.0,
            2447.0,
            1684.0,
            2483.0
          ],
          "confidence": 0.9986786246299744
        },
        {
          "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
          "bbox": [
            332.0,
            4435.0,
            1425.0,
            4477.0
          ],
          "confidence": 0.9861846566200256
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT",
          "page": 2,
          "bbox": [
            986.0,
            294.0,
            2351.0,
            331.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 2,
          "bbox": [
            1564.0,
            676.0,
            1774.0,
            713.0
          ]
        },
        {
          "text": "ARTICLE 1",
          "page": 2,
          "bbox": [
            1561.0,
            1438.0,
            1776.0,
            1476.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 2,
          "bbox": [
            1532.0,
            1493.0,
            1803.0,
            1529.0
          ]
        }
      ]
    }
  ]
}